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METAL CONTAINING NUCLEOSIDES THAT FUNCTION AS THERAPEUTIC 
AND DIAGNOSTIC AGENTS AGAINST 
BRAIN CANCER  
 
JENNIFER NICOLE WILLIAMS  
 
 
 
 
ABSTRACT 
Nucleoside transporters are essential components for the hyperproliferative 
capabilities of brain cancer cells. These transporters play important roles to increase 
nucleoside metabolism which is necessary for higher levels of DNA and RNA synthesis.  
The goal here is to use a series of metal containing nucleoside (MCN) analogues as novel 
chemical agents to study how nucleosides are imported into cells. In addition, we expect 
that these MCNs will ultimately function as therapeutic and/or diagnostic agents for brain 
cancer. Concentrative nucleoside transporters (CNTs) and equilibrative nucleoside 
transporters (ENTs) represent the two classes of transporters that allow MCNs to travel in 
(and out) of brain cancer cells.  This study focuses on cyclometalated iridium nucleosides, 
designated Ir(III)-PPY, Ir(III)-BZQ, and  Ir(III)-PBO, that were tested on a glioblastoma 
brain cancer cell line, U87.  The therapeutic activities of these MCNs were tested against 
U87 glioblastomas using several biochemical methods.  Cell viability experiments 
demonstrate that all compounds induce cell death in a time- and dose-dependent manner.  
Ir(III)-BZQ was identified as the most potent MCN, exhibiting an effective concentration 
(EC50) of 10 µM after 48 hours of exposure.   
  ix 
The collective photophysical properties of these fluorescent MCNs were also used 
to visualize their intracellular distribution throughout localized regions of the cell.  
Fluorescent microscope images reveal the accumulation of Ir(III)-BZQ in the cytosol after 
4 hours of exposure while significant nuclear localization is detected at longer times (~24 
hours). This timing corresponds with the onset of cell death and provides insight into the 
mechanism of action of these MCNs. In addition, the cellular uptake and cytotoxicity of 
Ir(III)-BZQ is significantly reduced when U87 cells are pretreated with the natural 
nucleoside, adenosine.  Collectively, the ability to measure the uptake of MCNs coupled 
with their anti-cancer activities define these novel nucleoside analogues as “theranostic 
agents” – compounds that possess both therapeutic and diagnostic activities. 
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CHAPTER I 
INTRODUCTION TO CANCER, CHEMOTHERAPY AND DIAGNOSTICS 
1.1 Cancer Incidence  
Cancer is the second leading cause of death in industrialized countries such as the 
United States and ranks second only to cardiovascular disease. It is estimated that one in 
every four people in the United States will develop cancer during their lifetime.(1)                                                        
In 2014, it is estimated that approximately 1.4 million people will be diagnosed with some 
form of cancer.(2)                 This disease affects all segments of society. In this respect, all 
races and age groups are susceptible to cancer.  Despite over 60 years of basic and clinical 
research in oncology, there is still no cure for this insidious disease. As described below, 
individuals who are afflicted with cancer typically undergo several different treatments 
ranging from surgery, exposure to ionizing radiation, or treatment with various 
chemotherapeutic agents. The focus of this thesis is toward studying the anti-cancer effects 
of metal-containing nucleosides as a new class of chemotherapeutic agents. 
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1.2 Cancer as a Hyperproliferative Disease  
Cancer is a mutli-faceted disease that can arise from a number of inter-related 
causes that include self-sufficiency in growth signals, resistance to anti-growth stimuli, 
evasion of apoptosis, sustained angiogenesis, and invasion/metastatic potential.(3)                                                               
However, one of the most recognizable features of most cancers is limitless replicative 
potential in which their hyperproliferative nature is characterized by uncontrollable DNA 
synthesis. This feature provides an important focal point for therapeutic intervention.  
One major target and biomarker for chemotherapeutic intervention is the 
characteristic increased production of DNA intrinsic to the hyperproliferative reproduction 
of cancer cells.(4)           As new therapeutic targets continue to be revealed, cell death can 
now be achieved in several mechanistic ways within hyperproliferative, cancer cells.  This 
intricate process of cell growth and preparation for reproduction is regulated by numerous 
checkpoints monitoring completion and accuracy of critical cellular events.  Consequently, 
proper progression onto the next phase of the cell cycle is dependent upon successful 
completion of the events involved in the current phase once a checkpoint is reached.(5)             
As new cells grow in your body via the normal process of cell division called mitosis, old 
cells die naturally via the process called apoptosis.(6)            Cancer is amongst many 
different types of diseases that are a result of the hyperproliferative capabilities of 
malfunctioning cells, causing uncontrolled cell growth.(7)   (4)             As this cycle 
continues in cancer cells, the cell’s ability to adhere to or recognize signals that tell it to 
grow, differentiate or die is somehow diminished.(8)             Understanding cancers and 
many other diseases is heavily dependent on identifying the molecular pathways that lead 
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to a loss of cell cycle regulation.  When does this loss of function lead to cancer?  There 
are a vast number of elements a cell requires or encounters within its lifespan that can be 
used as targets to develop chemotherapeutic agents and better understand these intricate 
cellular processes. 
When the cellular process of mitosis (M-phase) ends and cytokinesis has produced 
a new cell, one revolution of the cell cycle is complete.  The new cell produced will 
eventually begin to grow in size (G1-phase).   Once the cell has carried out specific 
instructions imbedded within its DNA blueprint, it eventually initiates the synthesis of 
more DNA (S-phase) before it finalizes its duties in the late phase of its life (G2-phase).  A 
normal cell should have doubled its DNA before it is finally ready to enter mitosis (M-
phase).(9)           Cells that are damaged during the cell cycle will undergo apoptosis if the 
cell cannot be repaired during the G2-phase. 
 
Apoptosis 
 When cells become defective, damaged beyond repair or are deemed unnecessary 
for developmental purposes, they undergo the process of programmed cell death known as 
apoptosis.  In addition to their hyperproliferative capabilities, one of the hallmarks of 
cancer cells is their ability to evade apoptotic cell death.   Because cancer cells lose this 
critical capability, damaged cells continue to proliferate uncontrollably.   This can directly 
lead to the accumulation of damaged cells that can become more and more abnormal. DNA 
damage associated with hyperproliferation and signaling imbalances resulting from 
elevated levels of oncogene signaling are amongst the most notable apoptosis-inducing 
stresses.(10)          Once the cell has unsuccessfully attempted a repair mechanism to correct 
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the damage, an orderly process of signals are produced to instruct the cell to commit the 
cellular version of suicide.   During this process, cell morphology changes as the cell begins 
to shrink in size as their chromatin condenses.  The apoptotic cell’s membrane remains 
intact as the cell is phagocytosed in vivo and its counterparts are recycled.  This process is 
contrary with the necrotic form of cell death associated with inflammation and cellular 
swelling followed by ruptured membranes and cell lysis.   
 There are two major signaling mechanisms that exist for the activation of apoptosis 
(extrinsic and intrinsic) that can be distinguished by their physiological pathways and 
biochemical factors.  Extrinsic apoptosis, or death receptor-mediated apoptosis, may or 
may not engage the intrinsic apoptotic, which is a Bcl-2 family-regulated pathway targeting 
the mitochondria.(11)         During the intrinsic apoptotic pathway cell death may be 
triggered through DNA damage or severe cell stress such as hypoxia and limited quantities 
of growth factor and/or nutrients.  As the mitochondrial exterior membrane increases in 
permeability, pro-apoptotic molecules such as cytochrome c are released from the 
mitochondria into the cytosol. Following activation, additional intracellular pro-apoptotic 
proteins are released to activate caspases that ultimately results in apoptosis.   
The extrinsic pathway is activated in response to diverse external cellular signals 
and death receptors on the surface of the plasma membrane such as the class of tumor 
necrosis factor receptors (TNFR).(12)         As ligands bind to these receptors, the extrinsic 
apoptotic pathway is activated by the formation of the “death inducing signaling complex” 
(DISC) resulting in the initiation of the caspase cascade through caspase 8.(13)        The 
extrinsic apoptotic pathway also has the potential to induce tumor cell death independently 
of the intrinsic pathway.(14)      Studying the interactions of proteins involved in both 
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pathways of apoptosis, intrinsic and extrinsic, will further advance the development of 
novel molecules for the treatment of apoptosis-related diseases such as cancer. (15)        
1.3 Current Chemotherapeutic Agents 
Indeed, there are a wide variety of therapeutic agents that inhibit DNA synthesis 
which is ultimately responsible for cellular proliferation (Figure 1).  Some 
chemotherapeutic agents are designed to interact with various checkpoints within the cell 
cycle that inhibit DNA synthesis taking place during the synthesis phase (G1/S-phase) of 
the cell cycle.  These are known as cell-cycle specific agents and represent a large 
percentage of the two major classes of specific and cell cycle non-specific 
chemotherapeutic agents.(16)            One example of a cell cycle specific agent is 
staurosporine.  Studies by Bruno and Ardelt show that leukemia Molt-4 cells treated with 
staurosporine were arrested in the G2-phase of the cell cycle.(17)            Although DNA 
replication continued and reflected clear changes in nuclear morphology, the treated cells 
did not undergo cell division.   Staurosporine was found to induce classical apoptosis in 
some cancerous cell lines and inhibit cell proliferation in a time- and dose-dependent 
manner by up to 90%.(18)            It is most effectively used today against cancers with an 
overexpression of PKC, such as colon cancer.  Further research identified it as a potent 
inhibitor of protein kinase-C (PKC), one of the various cyclin-dependent kinases that 
coordinates progression within the cell cycle.(16)           
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Figure 1. Many anti-cancer agents are cell-cycle specific as they are deigned to inhibit 
selective targets associated with efficient cell-cycle progression.(16)                      
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Naturally occurring chemotherapeutics like the plant alkaloids taxol and vincristine 
are also amongst cell cycle specific chemotherapeutic agents.(19)            These drugs are 
designed to target the mitosis phase (G2/M-phase) of the cell cycle by causing the inhibition 
of microtubule organelles and preventing the formation of mitotic spindles.(16)            This 
causes a cell to eventually self-terminate once the excessive amount of DNA present after 
cellular preparation for division causes a signal to be produced that now identifies this 
specific cell as an abnormal or mutagenic cell.   Further programming then instructs the 
cell to initiate termination via the normal cell death process (apoptosis).  Analogs such as 
vinblastine, vinblastine, docetaxel and other naturally occurring alkaloids (matrine and 
oxymatrine) have also shown anti-cancer potentials as cell cycle arrest agents, not to 
mention their known ability to possess anti-inflammatory, anti-fibrotic and anti-allergic 
effects.(20)             
Cell cycle non-specific agents, on the other hand, work by directly targeting the 
DNA polymerization process and its enzymes in order to damage/alter the structure of 
nucleic acids and base-pairs within DNA genes.  Few chemotherapy drugs used today can 
compare to the success of the DNA-damaging platinum complexes, such as cisplatin and 
its derivatives.  By forming stable DNA adducts and crosslinking lesions between 
nucleobase and spatially close residues that inhibit the function of DNA polymerases, these 
DNA damaging agent causes an apoptotic induced cell death.(16, 21)             Despite its 
efficacy against solid tumors, the development of less toxic analogs and other metal 
derivatives of cisplatin has resulted in equiactive complexes such as carboplatin and 
iproplatin.(22)            Therapeutic resistance to cisplatin has also been a driving factor in 
the development of numerous anti-cancer analogs including oxaliplatin, nedaplatin, 
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heptaplatin, lobaplatin and an extensive library of other platinum based derivatives.(23, 24)            
Other examples of DNA damaging agents include therapeutic agents such as chlorambucil, 
and cyclophosphamide also generate crosslinked lesions in DNA that prevent movement 
of the DNA polymerase.(25-29)                                                            
 
 
 Nucleoside Analogs Used as Therapeutic Agents 
Anti-metabolites are another type of cell-cycle non-specific chemotherapeutics and 
perhaps the largest class of anti-neoplastic agents that can produce multiple effects on DNA 
synthesis.  In this respect, nucleoside analogs are a promising type of antimetabolites that 
represent essential components for treating many lymphoproliferative disorders and some 
solid tumors. There are currently eleven FDA approved nucleoside analogs that account 
for ~20% of all drugs used in chemotherapy.(30)                 The structures for several of 
the most commonly used nucleoside analogs as well as their natural counterparts are 
provided in Figure 2. The primary pharmacological effect for nucleoside analogs is 
identical as they function as classic chain-terminators of DNA synthesis. However, 
nucleoside analogs are often subdivided into two distinct classes. The first class resembles 
purine nucleosides while the second resemble pyrimidine nucleosides. This distinction is 
not only based on differences in their chemical composition but also on differences 
observed in their pharmacodynamic and pharmacokinetic behavior.   
Unlike the purine analogs listed above, many chemotherapeutic nucleoside analogs 
also contain recognizable pyrimidine moieties that promote transport across the cell 
membrane.  Pyrimidine analogs such as gemcitabine and decitabine have also produced 
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promising improvements in the treatment of pancreatic cancer and some solid tumors.(31-
33)           transport. For example, the pyrimidine analog, cytarabine, displays a higher 
degree of toxicity against replicating cells compared to quiescent cells since it is primarily 
utilized during the S phase of the cell cycle.(34)              In contrast, purine analogs such 
as fludarabine and cladribine often display more cytotoxic effects against slowly 
replicating cells such as indolent lymphoma as these analogs can be incorporated into DNA 
during double strand DNA repair.(35-38)                
The use of a modified sugar such as an arabinose sugar opposed to a deoxyribose 
is a common example augmentation in analogs, as seen in in Figure 2.(39-41)            
Synthetic strategies in modification of the base or sugar moiety of the nucleoside continue 
to be investigated and support the need for developing new nucleoside analogs that have 
increased efficacy against solid tumors.  
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Figure 2. Comparison of the structures of natural nucleosides, adenosine and cytosine, 
with conventional nucleoside analogs used as anti-cancer agents.  
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The purine nucleoside analogs used most commonly used modern chemotherapy 
include fludarabine (9-β-D-arabinoside-2-fluoroadenine (FA)), cladribine (2-
chlorodeoxyadenosine (2′-CdA)), clofarabine (2-chloro-9-(2'deoxy-2'-
fluoroarabinofuranosyl)adenine), and pentostatin ( 2′-deoxycoformycin) (Figure 2).(42-
44)             These nucleoside analogs exert near exclusive cytotoxic effects against 
hematological malignancies such as chronic lymphoblastic leukemia (CLL), non-
Hodgkin’s lymphomas, Waldenström’s macroglobulinemia, and cutaneous T-cell 
lymphoma.(45-48)               2-CdA and pentostatin are noteworthy for their widespread use 
against hairy cell leukemia.(49, 50)                   These analogs possess chemical structures 
that are similar to (deoxy)adenosine. For example, the structure of 2-CdA differs from 
deoxyadenosine by the simple replacement of hydrogen with chlorine at the second 
position of the purine ring.  Fludarabine is a halogenated analog of adenosine in which 
fluorine is introduced at the second position of the adenine ring. Clofarabine is similar to 
cladribine as the hydrogen in the 2-position of the purine is replaced with chlorine. 
However, the deoxyribose moiety in cladribine contains a fluorine atom at the 2'-position. 
Pentostatin is a structural analog of deoxyadenosine that inhibits adenosine deaminase and 
thus exerts cytostatic and cytotoxic effects by disrupting nucleoside and nucleotide 
metabolism.(51, 52)                                                   
1.4 Problems Associated with Anti-Cancer Agents 
A major disadvantage of nearly every chemotherapeutic treatment is the fact that 
anti-cancer drugs also harm normal, healthy cells that share the same characteristic of fast 
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reproduction, such as hair, blood, bone marrow, reproductive and gastrointestinal cells.  
This leads to the common symptoms generally associated with chemotherapy such as 
nausea, fatigue, hair loss, vomiting, anemia and immune system suppression.(53-55)                                                        
A quantitative measure that is often used to gauge the potential safety of a drug is 
its therapeutic index which is calculated as the concentration of drug that produces 50% of 
a therapeutic response compared to the concentration that elicits 50% of a toxic or adverse 
response.(56)         TI can be further simplified as “the ratio of the dose that produces a 
toxic effect in 50% of a treated population (TD50) divided by the dose that produces a lethal 
effects in 50% of the population (LD50)”. (57)     When plotted, the ED50 and ID50 differ in 
their formation of the resulting sigmoidal curve.  ED50 results in an up-hill dose response 
curve that plots and increased response.  The ID50 resulting curve, on the other hand, is a 
down-hill dose response curve that plots and inhibitory response.    However, in this study 
the terms EC50, IC50, ED50 and ID50 can been used interchangeably, opposed to LD50 and 
TD50.  In animal studies, the therapeutic index is the lethal dose of a drug for 50% of the 
population (LD50) divided by the minimum effective dose for 50% of the population 
(ED50).  The dose that produces a toxicity in 50% of the population (TD50) is used to 
calculate the therapeutic index.in human clinical trials; instead, of lethality.   Due to the 
sever toxicities that occur with the administrating sublethal doses in humans, the lethal 
dose is generally reserved for determination in animal studies.  Because there are usually 
severe toxicities that occur at sublethal doses in humans, these toxicities often limit the 
maximum dose of a drug.(58)      
Figure 3 provides a graphical representation of therapeutic index in which the 
beneficial and toxic effects of a drug are plotted as a function of variable drug 
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concentrations.  According to a therapeutic index plot, the pictorial representation of a drug 
declared highly unsafe would show a narrow gap between the two curves generated based 
on the doses plotted that represent the desired therapeutic effects and the doses plotted 
representing a toxic effects.  Although lethal dose values are usually obtained in vitro or 
by laboratory animal studies, each variable in determining the therapeutic index represents 
a critical component when administering chemotherapeutics.   
As discussed above, the therapeutic index for many anti-cancer drugs is extremely 
low.  Values for therapeutic index can be as low as1.5 to 5 for compounds such as 5-
fluorouracil, cisplatin, and temozolomide.(59, 60)              In this thesis, I define the 
potential therapeutic index for two (2) new metal-containing nucleosides by measuring 
their cell-killing effects against hematological and adherent cancer cell lines versus non-
cancerous cell lines such as human fibroblasts.  
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Figure 3.  Therapeutic index (TI), which is defined as the ratio between the TD50 and 
ED50 (TI=TD50/ED50) is determined by measuring the frequency of desired responses 
and toxic responses as a function of variable drug concentrations.  
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1.5 Cancer Diagnosis 
Many types of tumors can be visualized by molecular imaging techniques such as 
molecular resonance imaging (MRI), computed tomography (CT), positron emission 
tomography (PET), single-photon-emission computed tomography (SPECT), and 
ultrasonography (US).  A surgical biopsy (a small extraction of the tumor that is analyzed 
by a pathologist under a microscope) will usually provide the most accurate diagnosis.  
This can either be performed during surgical resection or as a separate diagnostic 
procedure.(61-63)                                                                               
1.5.1 Molecular Detection of Cancer using Diagnostic Biomarkers and Agents 
The presence of a tumor as well as its progression can be identified by monitoring 
the abnormal signals and/or anatomical characteristics that resutls from changes in various 
metabolic and signaling pathways that occur in cancer cells.  Signals generated from the 
tumor itself or from irritation associated with the surrounding tissue can produce defined 
biomarkers that help doctors profile the cancer predisposition and state of 
development.(64)              A biomarker is defined as a characteristic within a cell that is 
objectively measured as an indicator of normal biological processes, pathogenic processes 
or pharmacological response to some form of therapeutic intervention.(65)                                                                                       
For example, glucose metabolism in cancer cells is significantly different compared to 
normal cells, and this difference represents an important biomarker for the detection of 
several types of cancer.    
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The physiological changes associated with the fermentation of glucose in the 
absence of oxygen in cancer cancers, commonly known today as the Warburg Theory of 
Cancer,    represents a biomarker that can be easily detected by clinicians when cancer is 
present.  The increase in glucose uptake associated with this change in cancer cell 
metabolism can monitored using 2’-deoxy-2’-(18F) fluoro-D-glucose (18F-FDG) as a 
surrogate for glucose.(66)             18F-FDG is considered the gold standard amongst all 
radioactive tracers used in the detection of cancer.(67)              At the molecular level, the 
substitution of a fluorine-18 atom for the hydroxyl group in the 2’ position of glucose, the 
radioactive tracer 18F-FDG can reveal specific physiological changes in the metabolism of 
this glucose analog during positron emission tomography (PET) scans.  The information 
resulting from the PET scan can be further quantified and manipulated to produce 3-D 
images of a tumor. As a result, an oncologist can define the location of most tumors as well 
as measure changes in mass that can occur in the absence and presence of treatment with 
therapeutic agents.  
While 18F-FDG is widely used to detect many types of cancer, its utility in brain 
cancer is limited since the uptake in normal brain tissue is considerably high. As such, it is 
nearly impossible to distinguish cancerous tissue from normal brain tissue due to low 
signal-to-noise-ratios. As a result alternative approaches and methods must be used to 
identify brain cancers effectively on a rapid time scale. Glioma and glioblastomas 
neoplasms are considered to be amongst the most aggressive brain tumors with the highest 
severity, resulting in a terminal cancer known as glioblastoma multiforme (GBM).(63)              
There are several biomarkers that are used to identify for GBM. These include the loss of 
heterozygosity (LOH) of specific chromosomes as well as promoters such as O(6)-
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methylguanine-DNA-methyltransferase (MGMT), which is the enzyme primarily 
responsible for removing DNA lesions caused by alkylating agents.(68, 69)                                                                                       
The limitations of biomarkers and current macroscopic imaging systems, however, often 
require them to be coupled to more advanced molecular probes and imagery forms to 
produce diagnostic platforms with increased spatial resolution and obtain molecular 
information that will enable the development of new imaging probes.(70)                                                                               
1.5.2 The Need for Improved Diagnostic Agents to Detect Brain Cancer 
Rapid diagnosis of cancer is essential for properly treating this disease. Indeed, it 
is well-recognized that early detection and diagnosis of cancer is key to generating better 
patient responses, most notably in reducing mortality rates. In fact, rapid and accurate 
diagnosis of cancer is now considered as important as the drugs used to treat this disease.  
This is especially true with brain cancers including glioblastoma.  Brain tumors are the 
second-largest killer of children and patients under the age of 34.(1)              In 2009 alone, 
there were approximately 190,000 individuals with brain tumors reported across the globe. 
Of these reported cases, over 140,000 died as a result of their brain cancer.(71)                 In 
the United State alone, approximately 20,000 individuals with brain cancers die annually. 
These epidemiological reports emphasize the incredible high mortality rate for most brain 
cancers.  However, an even more alarming feature is the rapid rate of death in patients with 
brain cancers. Specifically, only 13% of brain cancer patients live beyond 12 months after 
diagnoses, and only a mere 2% of patients live longer than two years.(72)                                                                                       
Because of the hyper-proliferative nature intrinsic to all malignant cancer cells, it can often 
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be only a matter of months between when a tumor is detected and when it has reached a 
size that causes death.   
Because the brain is compartmentalized, a person is generally diagnosed with brain 
cancer only after significant symptoms begin to appear. These symptoms, described below, 
are usually directly related to the location and size of the tumor.   For example, a person 
with a brain tumor might experience headaches or a lack in cognitive ability.  A loss in 
vision, on the other hand, might indicate that the tumor is located near the occipital or 
frontal lobes of the brain that control vision.  Emotional and behavioral changes such as 
difficulty speaking or swallowing and uncoordinated gait (a.k.a. “walking-on-a-boat 
syndrome”) are also symptoms that would be associated with a tumor being located within 
the brainstem.(73)                                                                    
 
Glioma and Glioblastoma Multiforme Tumors (GBM) 
 Within the central nervous system (CNS), nerve cells, or neurons, and glial cells 
are the main two types of cells that comprise brain matter.  Derived from the Greek word 
for “glue”, glia or glial cells outnumber neurons in the brain ten to one.(74)           A single 
neuron does not function individually amongst the billions of neurons in the human brain.  
Instead, a complex network of interconnection between neurons and glial cells enables a 
single neuron to directly communicate with thousands of other neurons and transmit 
electrical and/or chemical signals.(74)           Together, these cell counterparts make up the 
functional areas of the brain divided into the regions commonly known as the cerebellum, 
brainstem, motor and sensory strips and the frontal, temporal, occipital and parietal lobes 
or regions of the brain.(75)            
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Amongst glia, four major types of glial cells within the brain are key for the 
successful function and transmission of information within the brain. Astrocytes, 
oligodendrocytes, microglial cells and ependymal cells each play specific roles within the 
central nervous system (Figure 1).  Astrocytes help protect the brain by their formation of 
the blood brain barrier via surrounding capillary blood vessels within the brain.  These tight 
junctions formed by adjacent astrocytes create the barrier that restricts hydrophilic 
molecules and other constituents within the blood stream from entering the brain.  
Oligodendrocytes play an important role in the transfer of information from the neuron’s 
cell body (soma) down the axon and on to the axon terminal.  Adhering to the surface of 
the axon “tail” of the neuron, oligodendrocytes also increases the ability of axons to 
transmit signals quickly.  Microglial cells help rid the brain of dead, damaged or old cells, 
while ependymal cells are found at the junctions between the brain and the protective, 
nutrient rich cerebrospinal fluid (CSF).  Unlike glial cells, neurons do not have the ability 
to undergo cell division. Therefore, neurons typically only develop within children and 
although new neurons can be produced in adults (such as learning a new language), once 
these quiescent cells die, they cannot be replaced.  This is the reason why nearly all brain 
tumors such as Glioblastoma Multiforme (GBM) represents a type of cancer of the glial 
cells. 
Glioma and glioblastomas neoplasms are considered to be amongst the most 
aggressive brain tumors with the highest severity.(63)           The terms glioma and/or 
glioblastoma represent a class of malignant tumors associated with the central nervous 
system (CNS) and particularly the brain and spinal cord.  These primary tumors can be 
further separated into slow growing, benign tumors and faster growing, more severe 
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malignant tumors. To date, the pathogenesis and initiating factors that turn these normally 
functioning brain cells into hyperproliferative cancer cells remains unclear.  
 In general, the formation of malignant neoplasms in the confined area of the skull 
causes added pressure that can in turn lead to numerous side effects ranging in severity 
from harmless to lethal.  Additionally, each individual case differs from patient to patient.  
With incredibly low survival rates for patients, early detection is often the best hope for 
treating glioblastoma tumors. The lack of effective chemical entities to detect this type of 
cancer drives the need for improved diagnostic agents for brain cancer patients.(71)              
In this thesis, I interrogate the use of novel fluorescently-labeled nucleoside analogs as a 
spectroscopic probe to detect brain cancer cells. This approach is based on the hypothesis 
that the hyperproliferative nature of brain cancer cells necessitates the requirement for high 
levels of nucleosides needed for DNA and RNA synthesis.  My research will use metal-
containing nucleosides as fluorescent surrogates to visualize uptake into brain cancer cells 
and compare that towards uptake in non-cancerous fibroblasts.   Because of their 
nucleoside analog structure, metal containing nucleosides should surpass the limited 
capability of other chemotherapeutics that are not suitable for brain cancer because they 
cannot pass the blood brain barrier.  I hypothesize that there will be a difference in the 
uptake in these metal-containing nucleosides, and these results will provide initial evidence 
to further evaluate using these analogs as potential diagnostic probes for cancer detection.   
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1.6 The Role of Nucleoside Transporters in Normal Cell Homeostasis 
Nucleosides and their corresponding nucleotides play important roles in cell 
physiology by functioning as both nutrients and modulators of cellular homeostasis. For 
example, nucleoside triphosphates such as ATP and GTP are widely used as energy sources 
for various biological reactions.(76, 77)              In addition, nucleosides participate as 
ligands for purinergic receptors and transducers of endocrine signals and thus modulate a 
wide variety of cellular events.  Adenosine is a particularly important inflammatory 
modulator as increased extracellular adenosine levels activate the A2a receptor on the cell 
surface of immune cells.(78-81)              Finally, nucleosides are the monomeric building 
blocks of DNA and RNA and thus play central roles in the storage and expression of genetic 
information.  
 In general, regulating the intra- and extracellular concentration of nucleosides 
influences important physiological processes ranging from cardiovascular activity to 
neurotransmission to cellular proliferation.(82)             Nucleoside and nucleotide 
biosynthesis are energetically costly processes and thus generally restricted to selected cell 
types.(83)              In fact, it is more efficient for cells to obtain essential nucleosides 
through salvage and/or nucleoside recycling pathways than through de novo synthesis.  As 
such, the first and arguably most important step in nucleoside metabolism is transporting a 
nucleoside past the plasma membrane (Figure 4).  Since nucleosides and nucleotides are 
rather hydrophilic, they show negligible permeability across hydrophobic cellular 
membranes. To facilitate uptake, cells use specific proteins to efficiently translocate 
nucleosides from the extracellular milieu into the cytosol.  There are two types of cellular 
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nucleoside transport - an equilibrative transport mechanism that shows broad specificity 
but relatively low affinity for substrates, and a Na+-dependent, concentrative and high 
affinity transport process that exhibits some substrate specificity (Figure 4). These two 
types of nucleoside transport processes are catalyzed by classes of membrane-bound 
proteins designated as concentrative (CNT) or equilibrative nucleoside transporters (ENT). 
The human ENT family of membrane proteins is represented by four members (designated 
hENT1-4) that contain a predicted protein topology of 11 transmembrane helices.(84, 85)             
The best-characterized members of the family, hENT1, hENT2, and hENT3 show similar 
broad selectivities for purine and pyrimidine nucleosides.(86, 87)                       However, 
hENT2 and hENT3 differ as they can also transport nucleobases.(88)                     hENT4 
is unique in its selectivity for adenosine and its ability to transport a variety of organic 
cations.(89)                                    
There are three subtypes of hCNT transporters that contain 13 transmembrane 
domains as opposed to 11 transmembrane helices found in hENTs.(90, 91)             While 
all three CNTs are Na+-dependent, they differ in nucleoside specificity. For example, 
hCNT1 prefers pyrimidine nucleoside transport, hCNT2 is purine preferring, and hCNT3 
shows broad substrate specificity. In general, CNT family members display Km values for 
measuring nucleosides that are ~10-fold lower than those displayed in ENT family 
members.(92)                                   
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Figure 4. There are two types of cellular nucleoside transport, an equilibrative 
transport mechanism and a concentrative transport mechanism. 
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1.7 The Role of Nucleoside Transporters in Cancer Chemotherapy 
 The therapeutic activity of many nucleoside analogs used as anti-cancer agents is 
often limited by their cellular uptake and subsequent metabolism to the corresponding 
nucleoside triphosphate. In particular, the hydrophilic nature of most nucleoside analogues 
requires an active transport system to catalyze efficient cellular uptake.  Indeed, the cellular 
levels of nucleoside transporters can be used as predictive factors for patient responses, as 
seen with the nucleoside analog gemcitabine against pancreatic cancer and lung 
disease.(32, 93, 94)                For example, Fludarabine is a prodrug that must first be 
converted from the monophosphate form to the free nucleoside, F-ara-A, prior to gaining 
cellular entry. This conversion is catalyzed by 5-nucleotidase and occurs readily in 
plasma.(35, 95)              After dephosphorylation, the free nucleoside must enter the cells 
via the action of one of several nucleoside transporters.  
  Once inside the cell, most purine nucleosides accumulate mainly as the 
corresponding 5′-triphosphate. In the case of F-ara-A, the rate-limiting step in the 
formation of triphosphate is conversion of F-ara-A to its monophosphate which is catalyzed 
by deoxycytidine kinase.(96, 97)                       Although F-ara-A is a poor substrate for 
this pyrimidine kinase, the high specific activity of this enzyme in lymphoid tissues results 
in overall efficient phosphorylation. The monophosphate is converted to the diphosphate 
by AMP kinase, and then to the corresponding triphosphate by nucleoside diphosphate 
kinase.(98)                             
  25 
1.8 Applying Metal-Containing Nucleosides as Diagnostic Agents 
Since nucleoside transporters play key roles in mediating the uptake of several 
nucleoside analogs that function as anti-cancer agents, it is important to develop chemical 
entities that can accurately and easily measure their individual and composite activities at 
the cellular and organismal level.  Most contemporary approaches quantify cellular uptake 
by using isotopically-labeled nucleosides. This reliance unfortunately produces several 
logistical problems such as special requirements for synthesis and the use of discontinuous 
time-based assays to monitor nucleoside influx and/or efflux.(99, 100)          Finally, the 
use of radiolabeled nucleosides has obvious limitations toward measuring nucleoside 
transport and tissue distribution in humans.  
To combat these deficiencies, the Berdis lab recently developed a metal-containing 
nucleoside analog designated, Ir(III)-PPY nucleoside. This novel analog contains iridium 
embedded within a bis-cyclometallated scaffold attached to a deoxyriboside (Figure 
5).(101, 102)              The design of this metal-containing nucleoside was driven by several 
factors. First, it is well-established that cyclometalated complexes are highly stable and 
thus are capable of withstanding the aqueous environment of a living cell.(103, 104)             
Secondly, these complexes are phosphorescent luminophores that emit light.(105)            A 
particularly interesting feature is that they are subject to rational tuning to emit visible light 
across a range of wavelength.  In this case, triplet luminescence arises from either a metal-
to-ligand charge-transfer (MLCT) state or a ligand-centered excited state.(106-113)     
Metal containing nucleosides should surpass the limited capability of other 
chemotherapeutics that are not suitable for brain cancer because they cannot pass the blood 
  26 
brain barrier.            Finally, the attachment of a deoxyribose moiety to bis-cyclometallated 
scaffold was predicted to enhance cellular import via the activity of one or more nucleoside 
transporters.  
The Berdis lab used Ir(III)-PPY nucleoside as a prototypical metal-containing 
nucleoside to generate several lines of biochemical evidence indicating that this metal-
containing nucleoside functions as a “theranostic agent”, i.e., a compound that possesses 
both therapeutic and diagnostic activity against cancer cells.  In particular, cell-based 
studies revealed that Ir(III)-PPY nucleoside produces anti-cancer effects against the 
cervical cancer cell line, KB3-1. In addition, the metal-containing nucleoside rapidly 
enters cells via the activity of a specific nucleoside transporter designated hENT1. 
Finally, co-localization studies using high-field microscopy techniques demonstrated 
that Ir(III)-PPY nucleoside accumulates in the nucleus and mitochondria of these cancer 
cells. This last feature indicates that the metal-containing nucleoside is a novel chemical 
probe that can measure nucleoside distribution at the cellular level. The goal of this 
thesis is to extend these findings and further test the ability of Ir(III)-PPY nucleoside 
and other related analogs to function as “theranostic” agents against brain cancer.  
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Figure 5. Structural comparison of the two metal containing nucleosides (MCNs) 
primarily used in this work. 
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CHAPTER II 
PHARMACOLOGICAL STUDIES EVALUATING THE THERAPEUTIC 
ACTIVITY OF METAL-CONTAINING NUCLEOSIDES AGAINST BRAIN 
CANCER CELLS 
 
2.1 Abstract 
Nucleoside transport is an essential process that helps maintain the 
hyperproliferative state of most cancer cells. As such, this process represents an important 
target for developing therapeutic agents to treat cancer. This chapter integrates the ability 
of two metal-containing nucleosides, Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside, 
to produce anti-cancer effects the human brain cancer cell line, U87. The anti-cancer effects 
of Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside are both concentration- and time-
dependent. Dual parameter flow cytometry analyses validate that these nucleoside 
analogues cause apoptosis. Pre-treating cells with known nucleoside transport inhibitors 
reduces the cytotoxicity of Ir(III)-PPY nucleoside by blocking its cellular uptake. However, 
pre-treatment with NMBPR does not block the cellular uptake of Ir(III)-BZQ nucleoside.  
These results indicate that cellular entry of Ir(III)-PPY nucleoside is mediated by the 
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human equilibrative nucleoside transporter one (hENT1) while transport of Ir(III)-BZQ 
nucleoside occurs via a different pathway involving one or more other nucleoside 
transporters. Collectively, these data provide evidence for the development of a metal-
containing nucleoside that functions as a therapeutic agent against brain cancer that uses 
nucleoside transporter activity to facilitate cellular entry.   
2.2  Introduction 
Treatment for most brain tumors consists of a combination of three options: 
surgery, radiation, and/or chemotherapy.  The exact treatment regimen depends heavily on 
when the malignancy is diagnosed as well as the grade of the malignancy. For example, 
surgical resection is reported to be the primary form of treatment for more than 60% of 
patients with stage 1 brain tumors that have low proliferation rates. However, this option 
decreases to 6% in patients with stage three brain tumors that have high proliferation 
rates.(114)             As a result, the combination of surgical resection and radiation therapy 
has been the most significant advancement in treating GMB over the past fifty years.(115)               
In general, an additive cell-killing effect is seen when both forms of treatment as combined 
with chemotherapy, and this leads to better patient responses. The use of radiation therapy 
as a single agent, however, has yet to be matched by any form of chemotherapy.(99)                                                                                 
In cases with tumors considered to be too far advanced, the goal of treatment is 
palliative care that focuses primarily on relieving symptoms rather than curing the patient 
of cancer.  The efficacy of any individual treatment option or combinations of therapies 
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depends on the patient and specific tumor characteristics.  This is often the case in pediatric 
and geriatric patients where surgery and ionizing radiation can potentially cause more harm 
than good.(116)                                                                                 
The current treatment for GBM is the combined use of surgery, radiation therapy, 
and the chemotherapeutic agent, temozolomide.(117)            One of the most difficult 
problems associated with successfully treating primary brain tumors like GBM is the 
inability of most chemotherapeutic agent to cross the blood brain barrier.  In this case, 
temozolomide is unique as it can pass the blood brain barrier more effectively than other 
therapeutic agents such as monoclonal antibodies and small, hydrophilic molecules.   While 
considered the frontline chemotherapeutic agent for GBM, treatment with temozolomide 
still has a very poor prognosis as most patients tend to develop resistance to this drug within 
months.  The mechanism for the development of resistance to temozolomide is believed to 
arise from alteration in various DNA repair pathways and/or the misreplication of damaged 
DNA created by temozolomide. As a cell-cycle non-specific DNA alkylating agent, 
temozolomide methylates the O6 position of guanine (O6-MeG), the N7 position of guanine 
(N7-MeG) and the N3 position of adenine (N3-MeA).(118)                                                                                
Different repair pathways are activated by the lesions generated by temozolomide. For 
example, correction of the N7-MeG and N3-MeG adducts is achieved via the activities of 
the base excision repair (BER) pathway, methylpurine glycosylase, and AP endonuclease.  
O6-MeG adducts can be directly repaired via the enzyme, O6-methylguanine DNA 
methyltransferase (MGMT), or the mismatch repair pathway (MMR).  Studies of GBM 
cells treated with temozolomide in the presence of an overexpression of the DNA repair 
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enzyme MGMT indicate that this repair process is expected to be a key factor in the 
development of resistance to temozolomide.(119)                                                                                 
A possible alternative to treatment with temozolomide is the use of anti-metabolites 
such as nucleoside analogs. Most nucleoside analogs are highly effective against different 
types of cancer. For example, acute lymphocytic leukemia (ALL) and acute myeloid 
leukemia (AML) are two different types of cancers that affect white blood cell components. 
Nucleoside analogs such as clofarabine and fludarabine are widely used to treat these 
hematological cancers.(120)        Unfortunately, the efficacy of these drugs against solid 
tumor forms of cancer is not as robust.  In this Chapter, I present quantitative data 
examining the ability of metal-containing nucleosides to function as anti-cancer agents 
against glioblastoma, an adherent cancer cell line. The goal of this thesis work is to evaluate 
the ability of a novel class of metal-containing nucleoside analogs to produce a therapeutic 
effect against cancers that have limited treatment options such as glioblastoma multiforme 
(GBM).   
2.3  Materials and Methods 
Materials.  
Phosphate-buffered saline (PBS), antibiotic and antifungal agents, amphotericin, 
propidium iodide, PrestoBlue, DAPI, Alexa Fluor 588, and apoptosis assay kit containing 
Alexa Fluor 488-labeled Annexin V used for cell-culture studies were from Invitrogen. The 
human brain cancer cell line, U-87, was purchased from the American Type Culture 
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Collection (ATCC). The human acute lymphoblastic cancer cell line, MOLT4, and human 
fibroblasts were also purchased from ATCC.  
 
General cell culture procedures.  
All cells were cultured at 37 °C in humidified air with 5% CO2. Adherent cell lines 
were maintained in Dulbecco’s modified Eagle’s medium (Mediatech, VA) with 10% fetal 
bovine serum (USA Scientific), 100 g/mL penicillin (Invitrogen, NY), 100 g/mL 
streptomycin and 250 L gentamycin. The doubling time was approximately 24 hours. 
MOLT4 cells were maintained in Roswell Park Memorial Institute medium (RPMI-1640) 
supplemented with 4.5 mg/mL L-glutamine and 10% fetal bovine serum (FBS). 
 
Cell viability assays.  
The cytotoxic effects of Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside were 
quantified using a standard resazurin reduction assay (PrestoBlue), opposed to the more 
commonly known MTT tetrazonium assay.  Although both are colorimetric assays 
commonly used to measure cell viability, the resazurin reduction assay can measure both 
fluorescence and absorbance and is slightly more sensitive than tetrazonium reduction 
assays that measure absorbance.   They can also be incubated for shorter periods of time 
than MTT assays. 
Each cell was plated at a density of 20,000 cells/well in 96 well plates. Cells were 
incubated for 24 hours after plating to ensure proper adhesion. Metal-containing nucleoside 
was added to wells in a dose-dependent manner (1−100 M). Cells were treated with 
Ir(III)-PPY nucleoside or Ir(III)-BZQ nucleoside for variable time periods (24−72 hours). 
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At the desired time point, the original media was replaced with fresh media and 10 L of 
PrestoBlue reagent was added (Invitrogen, NY).  Conversion of the blue resazurin reagent 
to the pink resorufin product by viable cells was quantified, as a result of the ability of the 
inherent reducing power of the cellular cytosol. The fluorescence of each sample was 
measured using a microplate reader (Ex/Em = 560/590 nm). Raw data were normalized to 
100% viability (0.1% DMSO control), and EC50 values were obtained through a fit of the 
data to Equation 1. 
 
  y = 100% / (1 + (EC50/[Compound]))   (1) 
 
where [Compound] is the concentration of drug and EC50 represents the concentration of 
drug required to inhibit 50% cell growth.  The resulting sigmoidal/logistic curves were 
plotted and derived from the KaleidaGraph Synergy Software program.   The values 
calculated were also compared to those determined by other effective concentration 
analysis methods (Prism) and found more accurate and acceptable. 
 
Assessment of cell viability 
Cells were treated with DMSO (vehicle) and Ir(III)-PPY nucleoside (25 or 50 µM) 
or Ir(III)-BZQ nucleoside (10, 25 or 50 µM) was added in a time-dependent manner. Cells 
were harvested by centrifugation and washed in phosphate-buffered saline and re-
suspended in 100 µL of binding buffer containing 5 µM of AnnexinV-Alexa Fluor 488 
conjugate. Cells were treated with 1 µg/ mL propidium iodide (PI) and incubated at RT for 
15 min followed by flow cytometry analysis. After this incubation period, an additional 
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400 µL of 1X annexin-binding buffer was added. Cells were analyzed using band-pass 
filters with wavelengths of 525/540 nm and 620/630 nm with a flow cytometer (Beckman 
Coulter XL). 
For Hoechst 33342 staining, cells were grown overnight in 12-well cell culture 
dishes using an initial density of 100,000 cells/mL. Cells were then treated with variable 
concentrations of metal-containing nucleoside for time periods ranging from 4 to 24 hours. 
Images were obtained using an EVOSfl Advanced microscope using DAPI stain (Ex/Em 
=360/447 nm) as a positive control (0.1% DMSO control) with Hoechst 33342 (5 mg/mL). 
The wavelengths of the excitation and emission were 312 nm and 510 nm for the detection 
of the Ir(III)-PPY nucleoside.   
 
2.4  Results 
Cell-cycle analysis using propidium iodide (PI) staining was performed by treating 
cells (200,000 cells/mL) with variable concentrations of metal-containing nucleoside for 
time periods varying from 24 to 48 hours. After the appropriate time period, cells were 
treated with 0.25% trypsin and harvested by centrifuge at 3,000 rpm for 10 min. The 
supernatant was removed and the cells were washed with 1X PBS. The cells were then 
fixed with methanol and stored at −20°C overnight. Cell pellets were dislodged using 0.5 
mL solution of 10 µg/mL PI and 2 mg/mL of RNAase A in saponin-based permeabilization 
and wash buffer and then incubated for at 15 min prior to flow cytometry analysis. 
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2.4.1  Defining the potency of Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside 
against the brain cancer cell line, U87 
PrestoBlue® was used to quantify the effects of various anti-cancer agents 
including Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside on cell viability.  By using the 
reducing power of viable cells to quantitatively measure their proliferation, PrestoBlue® 
functions similarly to other commercially available resazurin reduction assays.  The 
reducing environment within the cytosol of cells with an active metabolism converts 
resazurin, a blue compound with no intrinsic fluorescent value, into the highly fluorescent 
product, resorufin, which can be quantified by measuring a change in fluorescence.  The 
fluorescence values obtained in these studies were recorded at an excitation wavelength of 
560 nm and emission wavelength of 590 nm.  A direct correlation between fluorescence 
intensity and cell viability was made to quantify the viable cells (data not show).   
Initial studies evaluating the potential cytostatic and/or cytotoxic effects of MCNs 
were performed by treating U87 cells with a fixed concentration of 50 µM of either 
nucleoside for variable time frames (24 to 72 hours).  As a negative control, cells were 
treated with ~1% (v/v) of DMSO which was the solvent used to dissolve each MCN. Cells 
treated solely with DMSO were then normalized to 100% cell viability to account for any 
cytotoxic effect caused by the solvent.  
The data provided in Figure 6 illustrate a significant difference in the percentage 
of viable cells remaining after 24, 48 and 72 hour upon treatment with either MCN. In 
particular, 80% of cells treated with Ir(III)-PPY nucleoside remain viable 24 hours post-
treatment while only 20% of cells remain after being treated with identical concentrations 
of Ir(III)-BZQ nucleoside.  
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In addition, there was a time-dependency in the reduction of viable cells with each 
MCN. For example, treatment with Ir(III)-BZQ nucleoside produces a large reduction in 
viable cells after 48 and 72 hours of exposure.  In particular, less than 10% of the cells 
treated with Ir(III)-BZQ remain viable after 48 hours.  Similar but less robust effects were 
observed using Ir(III)-PPY nucleoside. Collectively, these data indicate that Ir(III)-BZQ 
nucleoside produces a more robust effect on cell proliferation and/or cell viability 
compared to Ir(III)-PPY nucleoside.  
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Figure 6.  Comparing the efficacy of MCNs against U87 brain cancer cells.  Ir(III)-
BZQ nucleoside is more potent than Ir(III)-PPY nucleoside, possibly due to 
structural features. All experiments were performed in triplicate.   
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The difference in the pharmacological effects between Ir(III)-BZQ nucleoside and 
Ir(III)-PPY nucleoside is striking, especially upon close inspection of the structures of each 
MCN. While both compounds contain hydrophobic and aromatic moieties, Ir(III)-BZQ 
nucleoside possesses a higher degree of aromaticity compared to Ir(III)-PPY nucleoside.  
The exact reason for the increased cytotoxicity of Ir(III)-BZQ nucleoside still remains to 
be determined. However, correlations between structural differences between Ir(III)-PPY 
nucleoside and Ir(III)-BZQ nucleoside with their biological activities may lead to the 
production of more potent MCNs. These potential mechanisms are further explored in 
Chapter 4. 
 
 
Ir(III)-BZQ nucleoside is more potent than Ir(III)-PPY nucleoside and Fludarabine.   
To better define the potency of these MCNs, additional experiments were 
performed treating U87 with variable concentrations of either MCN, ranging from 1 to 100 
µM). The effects of Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside on these cancer 
cells were evaluated at 24, 48 and 72 hour time intervals (Figure 7).  Cells were treated 
with DMSO and represent the negative control.  
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Figure 7. Dose- and time-dependent anti-proliferative effects of Ir(III)-PPY 
nucleoside and Ir(III)-BZQ nucleoside against U87 cells.  Samples were compared 
to fludarabine (positive control) and DMSO (negative control).  DMSO is less than 
1% toxic in cells. Each nucleoside concentration was varied from 1 to 100 M.  
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The effective concentration (EC50) values for Ir(III)-PPY nucleoside and Ir(III)-
BZQ nucleoside after 24 hours were determined to be 150.1 ± 4.5 µM and 18.9 ± 4.8 µM, 
respectively. After 48 hours of exposure, the potency of Ir(III)-BZQ nucleoside increases 
by approximately 2.5-fold as manifest in an EC50 value of 7.6 ± 2.4 µM. A similar time-
dependent increase in potency was observed with Ir(III)-PPY nucleoside as well. In this 
case, the EC50 value decreases ~3-fold, going from 150.1 ± 4.5 µM to 59.9 ± 4.6 µM, as 
seen in Table 1. Collectively, these data validate that Ir(III)-BZQ nucleoside is 
approximately 8-fold more potent than Ir(III)-PPY nucleoside.  In addition, the time-
dependent nature for the decrease in EC50 values could reflect a kinetic phenomenon 
involving active transport of each MCN into the cancer cell.  This last aspect is further 
explored below and in Chapter 3.  
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Table 1. EC
50
 values for Ir(III)-PPY nucleoside, Ir(III)-BZQ nucleoside, and 
fludarabine.   All values reflect the mean ± standard deviation from a total of 
three separate experiments.  
 
 
Time 
Fludarabine 
(µM) 
Ir(III)-PPY 
(µM) 
Ir(III)-BZQ 
(µM) 
24 hrs >100 150.1 ± 4.5 18.9 ± 4.8 
48 hrs >100 59.9 ± 4.6 7.6 ± 2.4 
72 hrs ~ 80 48.2 ± 4.5 6.9 ± 1.3 
 
 
 
 
 
 
  42 
 
The anti-cancer effects of these MCNs were next compared to the ant-cancer 
nucleoside, fludarabine.  While this nucleoside analog is currently used to treat 
hematological cancers, it is not as effective against solid tumors.  Data provided in Figure 
7 show the dose- and time-dependent effects of fludarabine against U87 cells. As expected, 
this conventional nucleoside analog shows low potency against this adherent cell line. In 
fact, an accurate EC50 value cannot be measured for fludarabine due in part to its low 
potency coupled with poor solubility. However, a lower estimate of ~80 µM for fludarabine 
is obtained after 72 hours of treatment. Direct comparison of the EC50 values for 
fludarabine with Ir(III)-BZQ nucleoside indicates that the metal-containing nucleoside is 
at least 13-fold more potent than the conventional nucleoside analog against brain cancer 
cells.  
2.4.2  Defining the potency of Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside 
against fibroblasts as a model, non-cancerous cell line.  
In order for MCNs to be considered effective chemotherapeutic agents, they should 
possess a wide therapeutic index and thus show high selectivity for affecting cancer cells 
while not affecting non-cancerous cells.  To interrogate the potential safety of these metal-
containing nucleosides, their anti-cancer effects were measured against human fibroblasts.  
As before, PrestoBlue® assays were used to measure EC50 values for Ir(III)-PPY 
nucleoside and Ir(III)-BZQ nucleoside against these non-cancerous cells. The effects of 
Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside on fibroblasts were evaluated at 24, 48 
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and 72 hour time intervals (Figure 8 ).  Cells were treated with DMSO and represent the 
negative control.  
 The data provided in Figure 8 directly compare the effects of Ir(III)-PPY 
nucleoside and Ir(III)-BZQ nucleoside against U87 versus fibroblast cells. As indicated, 
the potency of Ir(III)-PPY nucleoside is less against fibroblasts compared to U87. This is 
evident by comparing the high ED50 value of 227 +/- 71 µM measured for Ir(III)-PPY 
nucleoside against fibroblasts compared to the lower ED50 value of 92 +/- 25 µM measured 
for Ir(III)-PPY nucleoside against brain cancer cells. Similar results are observed with 
Ir(III)-BZQ nucleoside. In this case, the ED50 value for Ir(III)-BZQ nucleoside is 4-fold 
higher against fibroblasts compared to U87 cells (compare ED50 values of 35 +/- 6 µM 
versus 8.5 +/- 0.9 µM against fibroblasts and U87 cells, respectively). Table 2 provides a 
summary of ED50 values for Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside measured 
against U87 cells and fibroblasts.   
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Figure 8.  EC50 values for Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside measured 
against U87 and fibroblasts. In each experiment, cells were treated with variable 
concentrations (5, 10, 25, 50, and 100 µM) of each nucleoside analog for 48 hours. 
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Table 2.  The anti-proliferative effects of Ir(III)-PPY and Ir(III)-BZQ are time-
dependent.  Confirms that Ir(III)-BZQ is ~7-fold more potent than Ir(III)-PPY  Ir(III)-
PPY and Ir(III)-BZQ show a ~3-fold selectivity for U87 cells compared to fibroblasts  
 
 
Ir(III)-PPY Ir(III)-BZQ
Dt = 24 hours         106 +/- 21 M 315 +/- 85 M 26 +/- 6 M 73 +/- 20 M
U87              Fibroblasts U87 Fibroblasts
Dt = 48 hours         47 +/- 7 M 220 +/- 65 M 9.3 +/- 1.5 M 34 +/- 8.5 M
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In general, these data indicate that both metal containing nucleosides display more 
potent anti-proliferative effects against U87 cells compared to fibroblast. This result 
suggests that both compounds have a potentially acceptable therapeutic index. However, 
additional cell-based and animal studies are needed to fully explore the potential safety and 
utility of either Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside as anti-cancer agents 
targeting brain cancer.  
2.4.3  Comparing the efficacy and selectivity of Ir(III)-PPY nucleoside and Ir(III)-
BZQ nucleoside versus conventional anti-cancer agents against brain cancer 
Currently, the most effective drug used to treat GBM is temozolomide (TMZ), also 
known by the brand names Temodar, Temodal, and Temcad.  This agent induces cell death 
by damaging DNA, specifically causing the formation of O6-methylguanine, N7-
methylguanine, and N3-methyladenine DNA adducts. Unfortunately, resistance to 
temozolomide develops in patients as a result of increased levels of the DNA repair 
enzyme, O6-methylguanine DNA methyltransferase (MGMT).(121)                                                                
Dose-limiting hematologic toxicity also remains an issue with temozolomide treatment, 
and has resulted in the study of numerous regiments to increase the therapeutic effects of 
temozolomide.   
To evaluate the efficacy and selectivity of temozolomide against brain cancer, the 
anti-cancer effects of this compound were measured against U87 cells and fibroblasts as 
previously described using the PrestoBlue® assay to measure cell viability.  Data provided 
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in Figure 9 compares the effects of temozolomide against U87 cells and fibroblasts at 48 
hours post-treatment.  It is clear that temozolomide affects both cancerous and non-
cancerous cells equally well. As such, this particular anti-cancer agent shows a low 
therapeutic index. By inference, Ir(III)-BZQ nucleoside represents a potentially more 
effective therapeutic agent against brain cancer for two (2) reasons. First, the metal 
containing nucleoside has a wider therapeutic index compared to temozolomide (~4 versus 
1). Secondly, the potency of Ir(III)-BZQ nucleoside is significantly lower than 
temozolomide against brain cancer cells (compare ED50 values of 8.5 +/- 0.9 µM versus 
>100 µM for Ir(III)-BZQ nucleoside and temozolomide, respectively).  
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Figure 9.  Temozolomide displays low potency against glioblastoma (U87) cells and 
non-cancerous fibroblasts. In addition, temozolomide is non-selective as it affects 
both cell types equally.   
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Previously, I demonstrated that the nucleoside analog, fludarabine, was 13-fold less 
potent than Ir(III)-BZQ nucleoside against U87 cells (Figure 7). The low potency of this 
conventional nucleoside analog prompted testing against a hematological cell line to verify 
that the nucleoside analog does exert anti-cancer effects against hyperproliferative cells. In 
these experiments, I used the nucleoside analog, clofarabine, which is structurally similar 
to fludarabine. Experiments were performed measuring the potency of clofarabine against 
the acute lymphoblastic cell line, MOLT4, as well as the glioblastoma cell line, U87.  
MOLT4 cells were treated with variable concentrations of clofarabine (0.01 – 100 µM) for 
48 hours. After this time period, cell viability was measured via microscopy techniques 
using trypan blue staining to differentiate viable from non-viable cells.  The ratio of viable 
cells to total cell cells (viable and non-viable) was used to calculate the % viable cells as a 
function of nucleoside concentration,  and this value was used as an indication of the 
cytotoxic effects of the nucleoside analog. Results provided in Figure 10 show that 
clofarabine produces a robust cytotoxic effect against MOLT4 cells. A plot of % viable 
cells as a function of clofarabine concentration yields a sigmoidal dose-response curve 
from which an LD50 value of 220 +/- 20 nM is obtained through a fit of the data to Equation 
(1).  
Similar experiments testing the efficacy of clofarabine against U87 yield 
significantly different results. In this case, treating U87 cells with the conventional 
nucleoside analog produces a minimal effect on cell viability as there is only a ~15% 
reduction in cell viability at the highest concentration of clofarabine tested (100 µM). 
Collectively, these results demonstrate that clofarabine is a highly effective anti-cancer 
against hematological malignancies such as acute lymphoblastic leukemia as illustrated by 
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its high potency. However, it is not effective against adherent cancer cells such as brain 
cancer cells. Again, the implication of this result is that Ir(III)-BZQ nucleoside is a more 
efficacious nucleoside analog compared to fludarabine and clofarabine as a result of its 
higher potency. 
 
  51 
 
 
 
 
 
 
Figure 10.  Clofarabine displays high potency against acute lymphoblastic leukemia 
cells (MOLT4) but not against glioblastoma (U87) cells.  
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An additional experiment was performed to interrogate the selectivity of 
clofarabine against cancerous versus non-cancerous cells. In this experiment, the anti-
cancer effects of clofarabine were measured against U87 cells and fibroblasts as previously 
described using the PrestoBlue® assay to measure cell viability.  Results provided in 
Figure 11 indicate that clofarabine effects both cancerous (U87) and non-cancerous 
(fibroblast) cells equally. Again, this lack of selectivity indicates that clofarabine possess 
a low therapeutic index against adherent cells.  
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Figure 11.  Clofarabine shows low potency against both U87 cells and non-
cancerous fibroblasts. Both cell lines are affected equally by clofarabine, 
consistent with a lack of selectivity of this anti-metabolite against adherent 
cancer cells.  
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Determining the mechanism of cell death induced by metal containing nucleosides. 
The cellular mechanism by which Ir(III)-PPY nucleoside and Ir(III)-PPY 
nucleoside causes cell death in u87 cells was evaluated employing dual parameter FACS 
analyses to measure propidium iodide (PI) uptake coupled with Alexa Fluor 488 Annexin 
V conjugate staining. In this analysis, live cells (negative for either fluorophore) are easily 
distinguished from cells that are early apoptotic (annexin V positive and PI negative), late 
apoptotic (PI and annexin V positive), or necrotic (PI positive and annexin V negative). 
Results provided in Figure 12 show that treatment with 10 and 25 µM Ir(III)-PPY 
nucleoside, respectively, causes significant increases in early and late stage apoptosis 
compared to cells treated with DMSO. This result is consistent with experiments measuring 
cellular viability described earlier in which there was a dose-dependent decrease in cell 
viability. 
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Figure 12. Dual parameter flow cytometry analysis of U87 cells treated with Ir(III)-
PPY nucleoside (10 and 25 uM) and Ir(III)-BZQ nucleoside (10, 25 and 50 uM) for  
48 hours.  Analysis reveals again confirms that  Ir(III)-BZQ nucleoside is more 
effective than Ir(III)-PPY nucleoside as it induces a more robust apoptotic effect in 
U87 cells.  
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 Similar experiments were performed testing the ability of Ir(III)-BZQ nucleoside 
to induce apoptosis. Results provided in Figure 12 again show that treatment with 10, 25, 
and 50 uM Ir(III)-BZQ nucleoside leads to significant increases in both early and late stage 
apoptosis.  These results again recapitulate earlier results demonstrating that Ir(III)-BZQ 
nucleoside reduces cell viability in a  dose-dependent manner.  
 Table 3 summarizes the results of dual parameter flow cytometry analyses of 
treating U87 cells with Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside. These data 
provide three (3) important results.  First, the anti-cancer effects of both metal-containing 
nucleosides against U87 cells reflect apoptotic cell death rather than through a simple anti-
proliferative effect or by cell death caused by necrotic mechanism.  This distinction is 
important since apoptotic cell death is preferred over necrotic cell death as the latter can 
cause inflammation, septic shock, and/or edema.(122, 123)                       Each response 
can compromise a patient’s response to chemotherapy. Secondly, these data again 
demonstrate a dose-dependent effect on apoptosis. Finally, these results recapitulate earlier 
data demonstrating that Ir(III)-BZQ nucleoside is more potent than Ir(III)-PPY nucleoside.   
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Table 3. Summary of dual parameter flow cytometry analysis of Ir(III)-PPY nucleoside 
and Ir(III)-BZQ nucleoside against U87 cells.  
 
 
Condition Viable 
Early 
Apoptotic 
Late 
Apoptotic 
Necrotic 
DMSO 92.0% 1.9% 2.4% 3.7% 
50 µM Ir(III)-PPY 
nucleoside 
87.3% 5.6% 4.5% 3.1% 
50 µM Ir(III)-BZQ 
nucleoside 
65.7% 8.1% 13.8% 12.4% 
 
  58 
To further evaluate the underlying mechanism for the induction of apoptosis, flow 
cytometry using propidium iodide staining to measure cell-cycle progression in U87 cells 
treated with DMSO, 50 µM Ir(III)-PPY nucleoside or 50 µM Ir(III)-BZQ nucleoside was 
performed. The results of these experiments are provided in Figure 13. Untreated U87 
cells show a normal cell-cycle distribution for asynchronous diploid cells. In this case, most 
cells exist at G1 (74.6 +/- 3.3%) while smaller population of cells exist at S-phase (7.8 +/- 
1.3%), G2/M (13.5 +/- 2.2%), and sub-G1 (4.1 +/- 1.3%).  The sub-G1 population 
represents cells that are undergoing nuclear fragmentation, a hallmark of apoptotic cell 
death. Cells treated with 50 uM Ir(III)-PPY nucleoside show significant perturbations in 
cell-cycle progression compared to cells treated with DMSO.  In this case, there is a 
reduction in the population of cells that exist at G1 (51.6 +/- 2.5%) with concomitant 
increases in the population of cells at S-phase (16.4 +/- 3.3%), G2/M (20.8 +/- 1.8%), and 
sub-G1 (11.2 +/- 2.3%). These results provide clear evidence that the Ir(III)-PPY 
nucleoside induces apoptosis as manifest by the increase in sub-G1. In addition, there are 
significant increases in the percentages of cell populations at S-phase and G2/M.  
At face value, these results suggest that Ir(III)-PPY nucleoside can affect cell-cycle 
progression in diploid cells. Indeed, similar results were observed in KB3-1 cells treated 
with Ir(III)-PPY nucleoside (Choi, J-S., Gray, T. and Berdis, A. J. Submitted to 
Theranostic). In this cell line, the effect on cell cycle progression was more dramatic. In 
fact, the effects of Ir(III)-PPY nucleoside on cell-cycle distribution in KB3-1 cells could 
not be accurately determined using a standard diploid cell model. Instead, values were 
calculated using a diploid-tetraploid model in which there is a heterogeneous population of 
cells containing two and four sets of chromosomes, respectively. Using this model, the 
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diploid population of cells have significant alterations in cell-cycle progression as indicated 
by a decrease in cells at G1 (19.9 +/- 7.1%) coupled with increased cell populations at S-
phase (43.2 +/- 7.8%) and G2/M (36.9 +/- 2.9%). Tetraploid cells also showed 
perturbations in cell-cycle progression in which there was a decrease at G1 (34.2 +/- 1.0%) 
and S-phase (20.5 +/- 6.6%) coupled with an increase at G2/M (45.3 +/- 5.7%). Taken 
together, these results indicate that Ir(III)-PPY nucleoside affects cell-cycle progression in 
both cervical cancer cells (KB3-1) and brain cancer cells (U87). However, it is intriguing 
that Ir(III)-PPY nucleoside has a more pronounced effect towards inducing apoptosis in 
U87 cells compared to KB3-1 cells. The underlying cellular mechanism for this difference 
is unknown at this time. One possibility could reflect simple differences in cell type, i.e., 
epithelial versus glial cell.  Another possibility is differences in either cell line in the 
expression levels of key proteins involved in cell-cycle progression such as p53. 
Cells treated with 50 µM Ir(III)-BZQ nucleoside also show significant 
perturbations in cell-cycle progression compared to cells treated with DMSO.  In this case, 
the reduction in the population of cells at G1 (40.0 +/- 8.5%) coincides with a significant 
increase in the sub-G1 population of cells (45.5 +/- 9.3%). This increase in sub-G1 provides 
clear evidence that Ir(III)-BZQ nucleoside induces apoptosis. Again, the apoptotic effect 
induced by Ir(III)-BZQ nucleoside is substantially greater than that produced by treatment 
with Ir(III)-PPY nucleoside.  These data are consistent with the results described above 
using dual parameter flow cytometry to interrogate the mechanism of cell death.  It is also 
interesting to note that Ir(III)-BZQ nucleoside does not appear to affect cell cycle 
progression as does Ir(III)-PPY nucleoside. This statement is based on the fact that the 
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population of cells at S-phase (8.3 +/- 1.5%) and G2/M (6.2 +/- 2.2%) are similar to values 
obtained to cells treated with DMSO.   
Collectively, these data indicate that both Ir(III)-PPY nucleoside and Ir(III)-BZQ 
nucleoside cause cell death via an apoptotic pathway as opposed to necrosis. However, it 
is striking that Ir(III)-PPY nucleoside appears to affect cell-cycle progression in U87 
whereas Ir(III)-BZQ nucleoside has a minimal effect, if any, on cell cycle progression. 
Further studies will be needed to first confirm this result and then probe the underlying 
mechanism for this difference.  
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Figure 13.  Flow cytometry analysis of U87 cells treated with Ir(III)-PPY nucleoside 50 
µM) and Ir(III)-BZQ nucleoside (50 µM) for  48 hours. The higher levels of sub-G1 
DNA in Ir(III)-BZQ nucleoside treated cells indicates that it induces a more robust 
apoptotic effect than Ir(III)-PPY nucleoside in U87 cells. 
DMSO (Dt = 48 hours)
50 M Ir(III)-PPY nucleoside (Dt = 48 hours)
50 M Ir(III)-BZQ nucleoside (Dt = 48 hours)
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Investigating the nucleoside transporter(s) involved in the uptake of Ir(III)-BZQ 
Nucleoside.  
There are two distinct families of nucleoside transporters that include equilibrative 
nucleoside transporters (ENTs) and concentrative nucleoside transporters (CNTs).  In 
humans, there are four ENT isoforms (designated hENT1 through hENT4) that display 
broad transport activities for both pyrimidine and purine (deoxy)nucleosides, as discussed 
previously.  Each hENT isoform catalyzes the bidirectional transport of nucleosides 
following a concentration gradient.  hCNTs consist of three isoforms (hCNT1-3) and 
catalyze the transport of (deoxy)nucleosides against a gradient by coupling nucleoside 
movement with sodium or proton co-transport.(78-81)                     hCNT1 and hCNT2 
translocate pyrimidine and purine (deoxy)nucleoside, respectively, by a sodium-dependent 
mechanism whereas CNT3 shows broad substrate selectively and possesses the unique 
ability to translocate nucleosides in both sodium- and proton-coupled manners.(124)                      
 The goal here is to determine which nucleoside transporter is involved in the uptake 
of Ir(III)-BZQ nucleoside in U87 cells. Previous studies in the Berdis lab performed by Dr. 
Jung-Suk Choi demonstrated that Ir-PPY nucleoside is transported into KB3-1 cells 
primarily by the activity of hENT1 (Choi, J-S., Gray, T. and Berdis, A. J. Submitted to 
Theranostic). This was determined by demonstrating that cells pre-treated with the 10 µM 
S-(4-nitrobenzyl)-6-thioinosine (NMBPR), a specific inhibitor of hENT1, blocked the 
uptake of Ir(III)-PPY nucleoside by ~90% compared to cells pre-treated with DMSO.  
 In this study, I used a similar approach to evaluate if hENT1 participates in the 
uptake of Ir(III)-BZQ nucleoside. In these experiments, U87 cells were pre-treated with 
either DMSO (control) or 10 µM NMBPR for 24 hours. After this time, the media was 
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removed and replaced with media containing variable concentrations of Ir(III)-BZQ 
nucleoside in the absence and presence of 10 µM NMBPR. Cells were analyzed after 48 
hours using PrestoBlue dye to measure cell viability.  The results of these experiments are 
provided in Figure 14.    
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Figure 14. hENT1 does not participate in the cellular transport of Ir(III)-BZQ 
nucleoside. Pre-treatment of U87 cells with 10 M NMPBR has no effect on the anti-
cancer effects of Ir(III)-BZQ nucleoside. 
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Table 4.  A summary of the Ir(III)-BZQ effective concentration (EC50) values 
measured in the absence ad presence of the hENT1 specific inhibitor NMBPR at 
10 M. 
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Representative data provided in Figure 14 shows that the inclusion of the hENT1 
inhibitor has essentially no effect on reducing the anti-cancer effects of Ir(III)-BZQ 
nucleoside against U87 cells.  This analysis was performed twice, and the collective results 
are summarized in Table 4. As indicated, the ED50 values for Ir(III)-BZQ nucleoside are 
not altered significant by the presence of NMBPR, and indicate that hENT1 does not likely 
participate in the transport of this metal-containing nucleoside. By interference, it is likely 
that another nucleoside transporter, either equilibrative or concentrative, is involved in the 
uptake of Ir(III)-BZQ-nucleoside. Alternatively, the metal-containing nucleoside may gain 
cellular access by simple passive diffusion. These potential mechanisms are explored 
further in Chapter 3 using the unique spectroscopic properties of these metal-containing 
nucleosides to visualize their cellular uptake.   
However, additional experiments were performed to further define the nucleoside 
transporter responsible for the uptake of Ir(III)-PPY nucleoside. In these experiments, U87 
cells were pre-treated with either DMSO (control) or 10 µM NMBPR for 24 hours. After 
this time, the media was removed and replaced with media containing variable 
concentrations of Ir(III)-PPY nucleoside in the absence and presence of 10 µM NMBPR. 
Cells were analyzed after 48 hours using PrestoBlue dye to measure cell viability. The 
results of these experiments, provided in Figure 15, illustrate that co-treating cells with 10 
µM NBMPR and metal-containing nucleoside generates higher levels of viable cells 
compared to cells treated with Ir(III)-PPY nucleoside alone. More precisely, pre-treatment 
of U87 cells with 10 µM NMPBR causes a “right-shift” in the dose response curve for 
Ir(III)-PPY nucleoside, indicating that the potency of Ir(III)-PPY nucleoside is lowered by 
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the hENT1 inhibitor. At the molecular level, the chemoprotective by NMBPR occurs by 
inhibiting hENT1 which then blocks the cellular transport of Ir(III)-PPY nucleoside.  
These results are consistent with data showing that NBMPR treatment can produce 
a chemoprotective effective against Ir(III)-PPY nucleoside in KB3-1 cells. Collectively, 
these data support a mechanism in which Ir(III)-PPY nucleoside enters cells via an active 
transport mechanism catalyzed by hENT1.  Surprisingly, the structurally related analog, 
Ir(III)-BZQ nucleoside, does not appear to be transported by hENT1 and therefore 
undergoes active transport by another nucleoside transporter or via passive diffusion.   
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Figure 15. hENT1 participates in the cellular transport of Ir(III)-PPY nucleoside. 
Pre-treatment of U87 cells with 10 M NMPBR causes a “right-shift” in the dose 
response curve for Ir(III)-PPY nucleoside, indicating that the hENT1 inhibitor 
lowers the potency of Ir(III)-PPY nucleoside by presumably blocking its cellular 
entry. 
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2.5 Discussion 
In this Chapter, I demonstrate that Ir(III)-PPY nucleoside and Ir(III)-BZQ 
nucleoside are novel metal-containing nucleosides that produce anti-cancer effects against 
the glioblastoma cell line, U87. Despite being structurally similar, the metal-containing 
nucleosides display unique features that highlight how subtle permutations in structure can 
produce different pharmacodynamic effects, This is evident as the potency of Ir(III)-BZQ 
nucleoside is ~8-fold lower than Ir(III)-PPY nucleoside.  This difference in potency reflects 
the ability of Ir(III)-BZQ nucleoside to induce apoptosis at lower concentrations. In this 
case, dual parameter FACS analyses measuring propidium iodide (PI) uptake and Alexa 
Fluor 488 Annexin V conjugate staining was used to demonstrate that  Ir(III)-PPY 
nucleoside and Ir(III)-BZQ nucleoside induce apoptosis rather than necrosis. These 
apoptotic effects are both dose- and time-dependent, and this result is consistent with 
previous results measuring cellular viability (vide supra).  However, perhaps the most 
striking difference is the fact Ir(III)-PPY nucleoside is transported by hENT1 while Ir(III)-
BZQ, the more potent analog, does not appear to an effective substrate for hENT1.  
These differences raise several intriguing questions regarding the higher potency of 
Ir(III)-BZQ nucleoside compared to Ir(III)-PPY nucleoside. One possibility could reflect 
different transport mechanism in which Ir(III)-BZQ nucleoside accumulates in cancer cells 
more rapidly than Ir(III)-PPY nucleoside. This particular question is addressed more 
thoroughly in Chapter 3 in which I use the spectroscopic properties of these metal-
containing nucleosides to measure their cellular import as well as evaluate their cellular 
distribution. Both pieces of information can provide unique information that can explain 
potential differences in potency.  However, in this chapter, I focus on attempting to explain 
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the molecular mechanism by which these metal-containing nucleosides induce apoptosis.  
I begin this by first reviewing what is known regarding the biochemical mechanisms of 
action for conventional nucleoside analogs such as fludarabine and clofarabine. The 
primary cytotoxic mechanism for most nucleoside analogs is incorporation of their 
corresponding nucleoside triphosphates into DNA, causing chain termination of DNA 
synthesis and the activation of apoptosis. For example, the mechanism for the incorporation 
of the triphosphate form of fludarabine (F-ara-ATP) by various human DNA polymerases 
has been extensively studied.(16, 28, 29, 125, 126)         Replicative polymerases such as 
pol , pol , pol , and pol incorporate F-ara-ATP after which DNA synthesis is 
inhibited.(35, 127)                 One incorporated into DNA, F-ara-AMP is a poor substrate 
for subsequent DNA elongation, making it an unusually effective chain terminator.  
Although it is a formal possibility that these metal-containing nucleoside acting as chain 
terminators, the data collected thus far is not consistent with this mechanism. Specifically, 
inhibiting cellular DNA synthesis by using chain terminating nucleosides usually induces 
cell-cycle arrest at S-phase. The flow cytometry data presented here (Figure 16) with 
Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside does not show evidence for cell-cycle 
arrest at S-phase. 
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Figure 16. (A) KB3-1 cells treated with Ir(III)-PPY nucleoside undergo apoptosis 
rather than necrosis. (B) The apoptotic effects of Ir(III)-PPY nucleoside reflect 
alterations in cell-cycle progression.  
A
B
DMSO treated
G1
S-phase
G2/M
G1
S-phase
G2/M
G1
S-phase
G2/M
50 M Ir(III)-PPY nucleoside
+ 10 M NBMPR
50 M Ir(III)-PPY nucleoside
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However, nucleoside analogs can also produce indirect effects on nucleic acid metabolism 
that can cause cell death. The predominant effect is by depleting cellular nucleotide pools 
via the inhibition of ribonucleotide reductase and various nucleoside kinases involved in 
converting natural nucleoside to their corresponding mono-, di-, and triphosphate 
metabolites.(98)       Since DNA replication requires high levels of cellular dNTPs, the 
depletion of nucleotide pools can delay cellular DNA synthesis. While not specifically 
examined here, this mechanism is also not consistent with the flow cytometry data.  As 
indicated above, inhibiting cellular DNA synthesis by depleting nucleotide pools would 
also likely induce cell-cycle arrest at S-phase. The flow cytometry data presented here with 
Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside does not show evidence for cell-cycle 
arrest at S-phase.  
Another important cytotoxic effect of purine nucleoside analogs, independent of 
directly inhibiting DNA synthesis, is via the induction of apoptosis by caspase activation. 
One classic feature of apoptosis is internucleosomal cleavage of genomic DNA that occurs 
after caspase activation. Caspase-3 is particularly important as it can be activated in the 
cytosol by dATP and cytochrome c.(6, 128)                 Since purine nucleoside analogs 
such as F-ara-ATP mimic dATP, they may function as surrogates to activate dATP-
dependent caspases and initiate apoptosis. Indeed, treatment with F-ara-ATP causes the 
induction of apoptosis both in cell culture systems and in primary chronic lymphocytic 
leukemia (CLL) cells.(36, 129, 130)                
Another possibility is that these metal-containing nucleosides inhibit ATP-
dependent kinases to produce an apoptotic effect. Indeed, the Berdis lab demonstrated that 
gold-containing indoles induced cell death in a time and dose dependent manner by 
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inhibiting various protein kinases.  Current work is underway to examine the ability of 
Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside to act as kinase inhibitors.  
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CHAPTER III 
CELL-BASED STUDIES EVALUATING THE POTENTIAL OF METAL-
CONTAINING NUCLEOSIDES TO FUNCTION AS NON-INVASIVE 
BIOPHOTONIC IMAGING AGENTS 
3.1  Abstract 
In Chapter 2 of this thesis, I demonstrated that the metal-containing nucleosides 
designated Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside produce anti-cancer activity 
against brain cancer cell lines. Despite being structurally similar, these nucleoside analogs 
displayed striking differences with respect to potency and dependency of nucleoside 
transporters for cellular uptake. In this chapter, I use the unique spectroscopic properties 
of these metal-containing nucleosides to further elucidate their mechanism of action.  
Microscopy studies measuring fluorescence associated with these analogs demonstrate that 
both Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside are taken up into U87 cells in a 
time- and dose-dependent manner. In this respect, the cellular uptake of Ir(III)-BZQ 
nucleoside is more efficient than that of Ir(III)-PPY nucleoside, and this difference 
correlates with measured differences in their potency.  Additional microscopy studies 
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demonstrate that pre-treatment with NBMPR, an inhibitor of hENT1, blocks the uptake of 
Ir(III)-PPY nucleoside but has no appreciable effect on the uptake of Ir(III)-BZQ 
nucleoside. These observations confirm the results of chemoprotective studies using 
NBMPR to block the cytotoxic effects of Ir(III)-PPY nucleoside but not that of Ir(III)-BZQ 
nucleoside. Collectively, these results demonstrate that Ir(III)-PPY nucleoside is a 
substrate for hENT1 whereas the related nucleoside, Ir(III)-BZQ nucleoside, is not.  
Finally, high-field microscopy studies were performed to define the intracellular 
localization of these metal-containing nucleosides in brain cancer cells. Preliminary data is 
provided indicating that both metal-containing nucleoside show complex patterns of 
localization that are both time- and concentration- dependent. However, microscopy 
evidence is provided indicating that both nucleoside analogs initially accumulate in the 
cytoplasm. In addition, Ir(III)-PPY nucleoside shows distinct accumulation patterns in the 
nucleus whereas the localization of Ir(III)-BZQ nucleoside appears to be primarily in the 
mitochondria. Results of these studies are discussed within the context of pharmacological 
studies previously described in Chapter 2.   
3.2   Introduction 
Understanding the hyperproliferative nature of cancer cells is critical to improving 
current treatments.  As cancer cells replicate abnormally fast, the efficient uptake and 
subsequent metabolism of nucleosides is essential for these pathogenic cell to support 
increased metabolism, DNA and RNA synthesis, and cell division.  Essential to this 
increased metabolism is the composite activity of various nucleoside transporters.  
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Concentrative nucleoside transporters (CNT) and equilibrative nucleoside transporters 
(ENT) represent the two classes of membrane proteins responsible for the influx of natural 
nucleosides into almost all types of cells.  
 Most contemporary approaches to quantify the cellular uptake of nucleoside 
employ isotopically-labeled nucleosides as surrogates. The reliance on this approach 
unfortunately produces several logistical problems such as special requirements for 
synthesis and the use of discontinuous time-based assays to monitor nucleoside influx 
and/or efflux.  In addition, the use of radiolabeled nucleosides has obvious limitations 
toward measuring nucleoside transport and tissue distribution in animals. To overcome 
these deficiencies, the Berdis lab recently developed a metal-containing nucleoside analog 
designated Ir(III)-PPY nucleoside, which contains iridium embedded within a bis-
cyclometalated scaffold attached to a deoxyriboside. Cyclometalated complexes of 
iridium(III) were chosen as rugged, cell-compatible emitters. In addition, these complexes 
are high-yielding phosphorescent luminophores that undergo rational tuning to emit visible 
light across a range of wavelengths.(102, 131-135)              
 As described earlier, there are two distinct families of nucleoside transporters that 
include equilibrative nucleoside transporters (ENTs) and concentrative nucleoside 
transporters (CNTs).  Humans possess four ENT isoforms, designated hENT1-4, that 
display broad transport activities for pyrimidine and purine deoxy(nucleosides).(136, 137)                
Each hENT isoform catalyzes the bidirectional transport of nucleosides following a 
concentration gradient.  There are three hCNT isoforms (hCNT1-3) that catalyze the 
transport of (deoxy)nucleosides against a gradient by coupling nucleoside movement with 
sodium or proton co-transport.(138, 139)                 hCNT1 and hCNT2 translocate 
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pyrimidine and purine (deoxy)nucleoside, respectively, by a sodium-dependent 
mechanism. hCNT3 is unique in that it translocates nucleosides by sodium- and proton-
coupled mechanisms. This brief overviews highlights the complexity of nucleoside 
transport, especially in pathogenic states such as cancer. The identification of specific 
nucleoside transporters that are overexpression and/or up-regulated is essential to better 
define pharmacological effects of conventional nucleoside analogs. As such, a goal of this 
chapter is to use metal-containing nucleoside as surrogates to gain a better understanding 
of the fundamental process of nucleoside transport. This information can then be 
extrapolated to further understanding the physiological processes involving drugs that 
induce cytotoxic effects against hyperproliferative diseases such as cancer.  The typical 
clinical method to measure a drug within the body are based on correlations between the 
levels of the drug in serum and other tissues as a function of time. As a result, it is very 
difficult to determine the minimum concentration of a chemotherapeutic agent that is 
necessary to produce the desired therapeutic effect without the harmful side effects 
associated with excess concentrations of drug.  With high emission yields and favorable 
luminescence lifetimes, the phosphorescent metal-containing nucleosides described here 
may serve as improved diagnostic tools for alternatives to currently used radiolabeled 
nuclides with the potential to replace the use of harmful radioactive materials. 
  An additional advantage of these unique analogs is their capability to demarcate 
their location inside the cell. Thus, a clear innovation of this study is to use these metal-
containing nucleoside analogs as novel chemical probes to reveal how nucleoside analogs 
accumulate into various cellular organelles. In this case, the ability to define their cellular 
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location can provide augmenting support for their function as anti-cancer agents as well as 
aid to identify potential cellular targets associated with their pharmacological effects.   
3.3  Materials and Methods 
Materials.  
Phosphate-buffered saline (PBS), antibiotic and antifungal agents, amphotericin, 
propidium iodide, PrestoBlue, DAPI, Alexa Fluor 588, and apoptosis assay kit containing 
Alexa Fluor 488-labeled Annexin V used for cell-culture studies were from Invitrogen. The 
human brain cancer cell line, U-87, was purchased from the American Type Culture 
Collection (ATCC).  
 
General cell culture procedures.  
All cells were cultured at 37 °C in humidified air with 5% CO2. Adherent cell lines 
were maintained in Dulbecco’s modified Eagle’s medium (Mediatech, VA) with 10% fetal 
bovine serum (USA Scientific), 100 µg/mL penicillin (Invitrogen, NY), 100 µg/mL 
streptomycin and 250 µL gentamycin. The doubling time was approximately 24 hours. 
MOLT4 cells were maintained in Roswell Park Memorial Institute medium (RPMI-1640) 
supplemented with 4.5mg/mL L-glutamine and 10% fetal bovine serum (FBS). 
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Microscopy studies to evaluate the cellular uptake of Ir(III)-PPY nucleoside and Ir(III)-
BZQ nucleoside.  
The uptake of Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside into U87 cells was 
visualized by microscope imaging. Cells were plated on 35 mm dish glass bottom 
microwell dishes and pre-incubated in the absence or presence of adenosine (200 µM) or 
NBMPR (10 µM). After 24 hours, cells were co-cultivated with Ir(III)-PPY nucleoside or 
Ir(III)-PPY nucleoside for time periods varying from 1 to 2 days. Cells were washed twice 
with PBS, and exposed to fresh medium in the presence of 1 mg/mL DAPI, Alexa Fluor 
568 phalloidin (1:2000), and/or 10 nM MitoPT-TMRE for up to 15 min. After this time, 
cells were washed twice with 1X PBS, fixed with 4% paraformaldehyde, and washed twice 
more with 1X PBS. Images were obtained using an EVOSfl Advanced microscope using 
DAPI stain (Ex/Em =360/447 nm) as a positive control (0.1% DMSO control) with 
Hoechst 33342 (5 mg/mL). The wavelengths of the excitation and emission were 312 nm 
and 510 nm for the detection of the Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside.   
Quantification of Ir(III)-PPY nucleoside uptake into KB3-1 cells was performed as 
previously described.  Briefly, cells were plated overnight onto 12 well plates at a density 
of 200,000 cells per well. The cells were then pre-incubated with DMSO or NBMPR for 
24 hours prior to treatment with variable concentrations of Ir(III)-PPY nucleoside for time 
intervals of 1 or 2 days. Cells were treated with 0.25% trypsin and harvested by 
centrifugation. The supernatant was removed and then washed twice with 1X PBS. Cells 
were lysed with 0.1% triton X-100 in 1X PBS, and then observed by fluorescent plate 
reader (Ex 340/Em 480). 
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3.4  Results  
Microscope imaging of cells treated with Ir(III)-BZQ nucleoside. 
Previous work in the Berdis lab demonstrated the uptake of Ir(III)-PPY nucleoside 
into KB3-1 cells occurs in a dose- and time-dependent manner. The studies described here 
use similar techniques employing fluorescence microscopy to evaluate the uptake of Ir(III)-
BZQ nucleoside into U87 cells. In these initial studies, cells were treated with 10 or 50 µM 
of Ir(III)-BZQ nucleoside. At variable time intervals (4-48 hours), cells were washed with 
PBS to remove metal-containing nucleoside, and images of treated cells were taken at using 
an excitation wavelength of 340 nm and an emission wavelength of 480 nm.   
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Figure 17. Fluorescence microscopy images demonstrate the accumulation of 
Ir(III)-BZQ nucleoside into U87 cells in a dose and time dependent manner. 
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Figure 17 provides images of cells treated with Ir(III)-BZQ nucleoside at variable times. 
These images provide clear evidence for an increase in fluorescence signal that reflects 
intracellular accumulation of the metal-containing nucleoside in U87 cells. This 
accumulation occurs in a time-dependent manner, and maximal accumulation of Ir(III)-
BZQ nucleoside occurs rather rapidly (within 8 hours post-treatment).  It should also be 
noted that these initial data indicate a dose-dependent effect on nucleoside uptake as judged 
by the higher fluorescence intensity detected using 50 µM Ir(III)-BZQ nucleoside 
compared to 10 µM Ir(III)-BZQ nucleoside. 
 
Correlating the uptake of Ir(III)-BZQ nucleoside with its pharmacological effects.  
The dose-dependency of the uptake of Ir(III)-BZQ nucleoside was similarly 
evaluated. In these experiments, U87 cells were treated with variable concentrations of 
Ir(III)-BZQ nucleoside for a fixed time interval (48 hours) and then analyzed via 
fluorescence microscopy to detect nucleoside uptake.  Data provided in Figure 18 shows 
that U87 cells treated with a low concentration of Ir(III)-BZQ nucleoside (5 µM) have few 
cells displaying a fluorescent signal. Since the emission intensity reflects intracellular 
accumulation of Ir(III)-BZQ nucleoside, a low signal is consistent with low cellular uptake. 
As the concentration of Ir(III)-BZQ nucleoside is increased, there is a concomitant increase 
in fluorescence signal that  represents a greater number of cells that have imported Ir(III)-
BZQ nucleoside.  Collectively, these microscopy data demonstrate a dose-dependency in 
the accumulation of Ir(III)-BZQ nucleoside. Taken together with the pharmacological 
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studies descried in Chapter 2, there is a qualitative correlation between the anti-cancer 
effect of Ir(III)-BZQ nucleoside with its cellular accumulation.  
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Figure 18.  U87 cells treated with a low concentration of Ir(III)-BZQ nucleoside have 
fewer cells displaying a fluorescent signal.  
DMSO 5 M BZQ 10 M BZQ 25 M BZQ 50 M BZQ
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Similar experiments were performed measuring the dose-dependency of the uptake 
of Ir(III)-PPY nucleoside.  Data in Figure 19 show that U87 cells treated with a low 
concentration of Ir(III)-PPY nucleoside have fewer cells displaying a fluorescent signal. 
As before, the emission intensity reflects intracellular accumulation of Ir(III)-PPY 
nucleoside. Thus, a low fluorescence signal reflects low cellular uptake. Similar to 
experiments performed using Ir(III)-BZQ nucleoside, there is an increase in fluorescent 
signal as the concentration of  of Ir(III)-PPY nucleoside is increased. These microscopy 
data also demonstrate a correlation between the anti-cancer effects of Ir(III)-PPY 
nucleoside with its cellular uptake. However, an important distinction is that these 
microscopy data highlight that the uptake of Ir(III)-PPY nucleoside is far less efficient 
compared to that for Ir(III)-BZQ nucleoside.  
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Figure 19. U87 cells treated with variable concentrations of MCN nucleoside analogs 
after 48 hrs correspond to the dose-response curves previously determined.  
DMSO 10 M PPY 50 M PPY
DMSO 10 M BZQ 50 M BZQ
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hENT1 facilitates the transport of Ir(III)-PPY nucleoside but not Ir(III)-BZQ nucleoside. 
To further interrogate the involvement of hENT family members in the transport of 
Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside, I next examined the ability of the hENT 
inhibitor, NBMPR, to block the fluorescence signals associated with the uptake of either 
metal-containing nucleoside. In these experiments, U87 cells were first pre-treated with 
DMSO or 10 µM NBMPR for 24 hours and then treated with fixed concentrations of Ir(III)-
PPY nucleoside (25 µM) or Ir(III)-BZQ nucleoside (10 µM) for another 48 hours. After 
this time period, cells were washed with PBS and then analyzed via fluorescence 
microscopy to detect nucleoside uptake.  Cells were also stained with DAPI  (1 ng/mL) to 
identify the nuclei of cells.  
  Microscope images (10X magnification) provided in Figure 20 demonstrate that 
U87 cells treated with 25 µM Ir(III)-PPY nucleoside and 10 µM NBMPR have 
significantly lower fluorescence intensities compared to cells treated with 25 µM Ir(III)-
PPY nucleoside in the absence of NBMPR. This result indicates that Ir(III)-PPY nucleoside 
enters cells via active transport catalyzed by  hENT1. This result confirms pharmacological 
data provided in Chapter 2 that demonstrated the chemopreventive effects of NBMPR 
against Ir(III)-PPY nucleoside.  
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Figure 20.  48-Hour MCN experiment with Ir(III)-PPY vs. Ir(III)-BZQ on U-87 in 
addition to pre-treatment with NMBPR Inhibitor (10X magnification) 
10 M NMBPR -> 10 M BZQ (Dt = 2 days)
25 M PPY (Dt = 2 days)
10 M BZQ (Dt = 2 days)
10 M NMBPR -> 25 M PPY (Dt = 2 days)
10X10X
10X10X
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  Contrasting results are obtained using Ir(III)-BZQ nucleoside. In this case, 
microscope images (10X magnification) provided in Figure 20 demonstrate that pre-
treatment of U87 cells with 10 µM NBMPR does not block the uptake of low 
concentrations of Ir(III)-BZQ nucleoside (10 µM). This is evident as the fluorescence 
intensities of cells treated with 10 µM Ir(III)-BZQ nucleoside alone are nearly identical to 
those obtained with NBMPR. This result indicates that Ir(III)-BZQ nucleoside does not 
function as a substrate for hENT1 and differs from the related analog, Ir(III)-PPY 
nucleoside, enters cells via active transport catalyzed by hENT1. Finally, the inability of 
NBMPR to block the uptake of Ir(III)-BZQ nucleoside result confirms results provided in 
Chapter 2 demonstrating that treatment with NBMPR does not produce a chemopreventive 
effect against Ir(III)-BZQ nucleoside.  
Figure 21 provides higher magnification images that further highlight the ability 
of NBMPR to block the uptake of Ir(III)-PPY nucleoside but not the uptake of Ir(III)-BZQ 
nucleoside into U87 cells. Collectively, these data indicate that hENT1 participates to 
facilitate the entry of Ir(III)-PPY nucleoside into cells. In contrast, Ir(III)-BZQ nucleoside 
does not appear to function as a substrate for hENT1. This dichotomy again highlights how 
subtle alterations in structure can affect substrate utilization by nucleoside transporters.  
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Figure 21.  48-Hour MCN Experiment:  PPY vs. BZQ U-87 Pre-treatment with 
NMBPR Inhibitor (40X magnification) 
10 M BZQ (Dt = 2 days) 10 M NMBPR -> 10 M BZQ (Dt = 2 days)
25 M PPY (Dt = 2 days) 10 M NMBPR -> 25 M PPY (Dt = 2 days)
40X40X
40X40X
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Sub-cellular localization of Ir(III)-BZQ nucleoside.  
Earlier, I presented data indicating that Ir(III)-BZQ nucleoside causes cell death via 
the induction of apoptosis. To further examine this mechanism, microscopy techniques 
were used to determine if Ir(III)-BZQ nucleoside localizes in the nucleus, mitochondria, or 
other cellular organelles that are typically affiliated with apoptotic pathways. This analysis 
is important as information regarding the localization of this metal-containing nucleoside 
could provide insight into which cellular target(s) is(are) being affected to generate an 
apoptotic response.  Imaging experiments were performed treating U87 cells with 10 or 50 
µM Ir(III)-BZQ nucleoside for time periods of 4 to 48 hours. At various time, cells were 
then co-stained with DAPI or MitoPT-TMRE to identify various cellular organelles 
(nucleus and mitochondria, respectively). Representative data provided in Figure 22 shows 
the microscopy images of U87 cells treated with 10 or 50 µM Ir(III)-BZQ nucleoside for 
48 hours and then stained with DAPI or MitoPT-TMRE to identify the nucleus and 
mitochondria, respectively.  
Cells treated with low concentrations of Ir(III)-BZQ nucleoside (10 µM) show 
moderate levels of green fluorescence, indicating uptake of the metal-containing 
nucleoside. The merged image of green fluorescence (reflecting the presence of Ir(III)-
BZQ nucleoside) coupled with DAPI staining (nuclear staining) does not show significant 
accumulation of the nucleoside in the nucleus.  Likewise, the merged image of green 
fluorescence (reflecting the presence of Ir(III)-BZQ nucleoside) coupled with MitoPT-
TMRE staining (mitochondria) also does not show significant accumulation of the 
nucleoside in the mitochondria.  Thus, under these conditions, it appears that the majority 
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of fluorescence signal generated using low concentrations of Ir(III)-BZQ nucleoside is 
confined to the cytoplasm.  
Treatment with higher concentrations of Ir(III)-BZQ nucleoside (50 µM) produces 
more pronounced effects. One obvious effect is that there are fewer cells present after 
exposure to this higher concentration of nucleoside, and the lower cell number is consistent 
with the dose-dependent cytotoxic effects of Ir(III)-BZQ nucleoside. Despite a reduction 
in cell number, each remaining cell displays a significantly higher level of green 
fluorescence that again represents the accumulation of the nucleoside within the cell. 
Merged images again do not show significant co-localization of Ir(III)-BZQ nucleoside in 
the nucleus of U87 cells treated for 48 hours. Instead, the merged image of green 
fluorescence (reflecting the presence of Ir(III)-BZQ nucleoside) coupled with MitoPT-
TMRE staining (mitochondria) shows significant accumulation of the nucleoside in these 
organelles.  The localization of Ir(III)-BZQ nucleoside in the mitochondria coupled with 
its cytotoxic effects suggest that Ir(III)-BZQ nucleoside induces apoptosis by altering 
mitochondrial activity.  This could be achieved by interfering with enzymes involved in 
ATP production or through the direct release of cytochrome c from the mitochondria. 
Alternatively, the metal-containing nucleoside may exert an apoptotic effect by interacting 
with nucleic acid, either RNA or DNA, inside the mitochondria. Future experiments are 
planned to evaluate these potential mechanisms and are described in Chapter 4.   
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Figure 22. Fluorescence microscopy images of Ir(III)-BZQ nucleoside uptake into U87 
cells. U87 cells were treated with two different concentrations of Ir(III)-BZQ (10 and 
50 µM) in the absence and presence of 2’-deoxyadenosine. Ir(III)-BZQ nucleoside 
emits green fluorescence.  Nuclei were stained with DAPI (blue), while mitochondria 
were stained with MitoPT (red).  The microscope magnification was 40X.  
  95 
 
 
 
 
 
 
 
 
Figure 23.  24-Hour MCN Experiment with U87 cells treated with Ir(III)-PPY vs. 
Ir(III)-BZQ. (60X magnification)  
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To further define the localization of Ir(III)-BZQ nucleoside in the mitochondria of 
U87 cells, similar experiments using higher magnification to more accurately visualize the 
nucleus and mitochondria. Preliminary results generated with the assistance of Dr. Jung-
Suk Choi, a post-doctoral fellow in the Berdis lab, are provided in Figure 23.  These images 
taken at 60X magnification were obtained after treating U87 cells with variable 
concentrations of Ir(III)-BZQ nucleoside (0, 10, 25, and 50 µM) for 48 hours. The merged 
image of green fluorescence (reflecting the presence of Ir(III)-BZQ nucleoside) coupled 
with DAPI staining (nuclear staining) does not show significant co-localization. This result 
again indicates that the metal-containing nucleoside does not appreciably accumulate in 
the nucleus.  Likewise, the merged image of green fluorescence (reflecting the presence of 
Ir(III)-BZQ nucleoside) coupled with Mito-PT staining (staining of mitochondria) shows 
some increase in co-localization, suggestive of accumulation of the nucleoside in the 
mitochondria.  Again, these results are preliminary and must be repeated to truly verify co-
localization of Ir(III)-BZQ nucleoside in mitochondria. One complication of this 
experiment is that there are significant morphological changes in U87 cells as the 
concentration of Ir(III)-BZQ nucleoside is increased. These changes occur as the metal-
containing nucleoside induces apoptosis in a time-dependent manner. As such, additional 
experiments will be performed at earlier time points (<24 hours) to avoid complications 
associated with cell death that occur at high concentration of the metal-containing 
nucleoside.  
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Sub-cellular localization of Ir(III)-BZQ nucleoside is dependent upon nucleoside transport 
activity.   
Additional experiments were performed to validate that co-localization of Ir(III)-
BZQ nucleoside is dependent upon nucleoside transport activity. As illustrated in the 
bottom panels of Figure 22, cells pre-treated with 200 µM 2’-deoxyadenosine have lower 
levels of Ir(III)-BZQ nucleoside in the cytoplasm and mitochondria.  The lack of 
localization occurs as adenosine blocks the uptake of the metal-containing nucleoside to 
effectively lower its intracellular concentration. These results again confirm that transport 
of Ir(III)-BZQ nucleoside across the cell membrane is dependent upon the activity a 
nucleoside transporter. However, the inability of NBMPR to block the uptake of Ir(III)-
BZQ nucleoside suggests that hENT1 is not responsible. By inference, Ir(III)-BZQ 
nucleoside enters U87 cell either via passive diffusion or through the activity of another 
nucleoside transporter.  
3.5  Discussion 
 The ability of chemotherapeutic nucleoside analogs to function as effective anti-
cancer agents relies heavily upon their cellular transport.  Because of their characteristic 
overexpression of CNT and ENT membrane transporters, cancer cells can import higher 
amount of nucleosides and deoxynucleoside which are required for increased levels of 
DNA and RNA for storing and expressing genetic information.  In general, the first step in 
nucleoside metabolism is the active transport of a nucleoside across the cell membrane via 
nucleoside transporters.  Two major types of nucleoside transporters are used to facilitate 
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the entry of natural nucleosides and their deoxynucleoside counterparts into brain cancer 
cells.  These include concentrative nucleoside transporters (CNTs) that are Na+-dependent 
transporters that move substrates into cells against the concentration gradient. The second 
class, equilibrative nucleoside transporters (ENTs), aid in the diffusion of nucleosides 
across the cell membrane and operate bi-directionally according to the substrate 
concentration gradient.  In this study, I demonstrated that metal-containing nucleosides 
accumulate within brain cancer cells in a dose and time dependent manner. This result 
suggests that these analogs can be effectively used as surrogates to effectively quantify the 
affinity of CNT and ENT membrane proteins for natural nucleosides through non-invasive 
techniques employing standard fluorescence microscopy techniques. In addition, these 
metal-containing nucleosides could be used to define the transport activity of nucleoside 
analogs that are used as chemotherapeutic agents.  Collectively, these studies described 
here have addressed the selectivity of membrane nucleoside transporters to determine the 
mechanism of how natural nucleosides are imported into cells.  
 
Metal-Containing Nucleosides enter U87 Cells via Active Transport  
  The results here show that each metal-containing nucleoside enters U87 cells via 
different mechanism.  At face value, the ability of the natural nucleoside 2-deoxy-
adenosine, to block the uptake of either metal-containing nucleoside indicates the 
involvement of an active transport system rather than simple passive diffusion. This active 
transport system likely involves the catalytic activity of one or more nucleoside transporter. 
This is clear since 2’-deoxyadenosine is a substrate for all hENT and hCNT family 
members and thus functions as a broad spectrum inhibitor for the uptake of these metal-
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containing nucleosides.(42, 140-142)               However, the use of NBMPR as a selective 
inhibitor of hENT1 allowed for further determination for the involvement of this particular 
transporter. Indeed, the data provided here indicates that Ir(III)-PPY nucleoside is 
transported by hENT1 as pre-treatment with NBMPR blocks its uptake in both U87 cells 
and KB3-1 cells. However, the same cannot be said for the uptake of Ir(III)-BZQ 
nucleoside as pre-treatment with NBMPR does not block its uptake into U87 cells. Thus, 
Ir(III)-BZQ nucleoside is most likely a poor substrate for hENT1 and must enter the cell 
via the activity of another nucleoside transporter. 
 
Subcellular localization 
Eukaryotic cells possess several organelles including a nucleus, Golgi apparatus, 
endoplasmic reticulum, lysosomes, and mitochondria. To function optimally, these 
organelles are spatially separated from each other by membranes that prevent uncontrolled 
movement of large (DNA, RNA, and proteins) and small (nucleosides/nucleotides) 
molecules. One goal of this thesis is to understand how organelles function independently 
and collectively. I hypothesize that this can be accomplished by accurately measuring the 
influx and efflux of important cellular metabolites. Studies described here employing 
metal-containing nucleosides have provided important information regarding the 
movement of nucleoside surrogates into distinct organelles.    
  My studies focused on two specific organelles, the nucleus and the mitochondria. 
The nucleus functions as the command center of a cell as it regulates many biological 
processes, most notably gene expression and the integrity of the genome encoding these 
genes. A double membrane encloses the nucleus and separates its contents from the 
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cytoplasm.  As such, the movement of large and small biomolecules required for RNA 
(transcription) and DNA metabolism (replication, repair, transcription) is mediated by 
pores that cross both membranes.  The mechanism of this tightly regulated process is poorly 
understood for lack of chemical entities that monitor macromolecules transport through the 
nuclear pore complex.   
 Mitochondria are another important organelle as they supply the cell with ATP that 
is needed for survival and proliferation. Often viewed as the cell’s “powerhouse,” 
mitochondria can also play destructive roles by initiating events required for apoptosis.  
Both processes are regulated by multiple signaling pathways, and I envision that the use of 
the metal containing nucleoside, particularly Ir(III)-BZQ nucleoside, will provide a deeper 
understanding of how nucleoside transport controls ATP synthesis and apoptosis.(143)                                                                        
With KB3-1 cells as a model system, the Berdis lab previously used high-field 
microscopy to demonstrate that Ir(III)-PPY nucleoside localizes inside organelles such as 
the nucleus and/or mitochondria that are heavily involved in nucleoside metabolism. 
Specifically, cells treated with 50 µM Ir(III)-PPY nucleoside showed high levels of green 
fluorescence that reflects uptake of the biophotonic nucleoside. Merged images showed 
co-localization of Ir(III)-PPY nucleoside with DAPI-stained nuclei, confirming that the 
metal-containing nucleoside showed significant accumulation in the nucleus. Similar 
experiments using MitoPT-TMRE to stain the mitochondria of KB3-1 cells also showed 
that Ir(III)-PPY nucleoside co-localized in the mitochondria. Other staining experiments 
indicated that Ir(III)-PPY nucleoside does not co-localize with other organelles including 
cytoskeleton, Golgi, or lysosomes (data not shown).   
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  The results provided here demonstrate that Ir(III)-BZQ nucleoside localizes in the 
cytoplasm and the mitochondria rather than the nucleus. On one hand, the localization of 
Ir(III)-BZQ nucleoside in the mitochondria is consistent with its ability to induce apoptosis. 
As described earlier, the mitochondria is not only the organelle responsible for ATP 
production but it is also involved in regulating apoptosis.  It is tempting to speculate that 
Ir(III)-BZQ nucleoside affects mitochondrial integrity which produces an apoptotic 
response due to the release of cyctochrome c, by inhibiting ATP synthesis, or a 
combination of the two.   Further experimentation is required to fully define these possible 
mechanisms.   Regardless of these outcomes, it is very surprising that Ir(III)-BZQ 
nucleoside and Ir(III)-PPY nucleoside show different localization patterns.  In this regard, 
Ir(III)-BZQ nucleoside appears to accumulate in the mitochondria while Ir(III)-PPY 
nucleoside shows accumulation in both the mitochondria and nucleus.   
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CHAPTER IV 
CONCLUSIONS 
There is an ongoing need for effective methods and devices to treat and diagnose many 
types of cancer.  Because proper treatment cannot be administered without an accurate 
diagnosis, efforts to improve current diagnostic capabilities have become just as important 
as treatment.  It has been over 50 years since the World Health Organization (WHO) set 
out to establish a tumor classification system that is accepted worldwide with the common 
goal to clearly define histopathological and clinical diagnostic criteria and epidemiological 
studies of cancerous tumors.(144, 145)    Tumor location, size, applied pressure, growth 
rate, place of origin and cell type are amongst the varied factors considered when 
classifying neoplasms and determine patient prognosis.   The research discussed herein 
supports the development of improved diagnostic tools that were later found to possess 
cytotoxic effects.   This was also an effort to prove that the highly effective, emerging class 
of nucleoside analogs used to treat many hematological cancers could be used to study the 
biodisposition and mechanisms occurring inside tumor cells.  
Given the success of conventional nucleoside analogs like fludarabine, there has 
been a shift in the development of nucleoside analogs with more diverse functions.  The 
high cytotoxic effect of current chemotherapeutics like fludarabine to treat many forms of 
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leukemia and gemcitabine against pancreatic cancer also support the notion of nucleoside 
analogues as favorable candidates to promote the development of new chemotherapeutics 
agents that are effective against neoplasms such as GBM.  One approach commonly used 
for the synthesis of new analogs of nucleosides is based on the augmentation of the ribose 
sugar portion of the nucleoside.  The analogs presented herein, however, will replace the 
basic ring component of the chemotherapeutic analog, opposed to sugar substitution.  The 
affinity of these potential therapeutic compounds for specific cell types that overexpress 
specific intramembranous proteins (CNT and ENT) also supported the hypothesis that 
these new compounds may lead to potential agents to treat other types of cancers and 
diseases that intrinsically possess the same characteristics.  Such is the case with other 
forms of cancer such as ovarian cancer and leukemia.  Base on the realization that an 
overexpression of nucleoside transporters is needed to support hyperproliferation of cancer 
cells, an in depth look into the interactions of nucleoside analogs with nucleoside 
transmembrane proteins has be evaluated. 
Many of the problems encountered in the diagnosis and treatment of gliomas can 
be confronted with a “theranostic” approach.  Coined by the German scientist John 
Funkhouser in 2002, the initial objective of theranostics was to describe a series of 
diagnostic test to guide personalized therapies.(146)     Within the past 10 years, however, 
the discipline has developed to include the dual ability of materials that can deliver a 
therapeutic effect while simultaneously serving as diagnostic imaging agents.  It has also 
been hypothesized herein that these biophotonic probes utilize specific CNT and ENT 
membrane proteins to enter hyperproliferative brain cancer cells.  The therapeutic activity 
of each of these MCNs against U87 glioblastomas cells has been measured using several 
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biochemical methods.   Findings in this study also contribute to establishing a better 
understanding of the proliferative nature of cancer cells, the identification of the selectivity 
of specific nucleoside transporters, the mechanism and rate of cell death, and the effect of 
MCNs when applied to non-cancerous cells models. 
Amongst the original objectives of this project were studies of the pharmacokinetics 
of metal containing nucleosides (MCNs) designed as luminescent photonic probes.  
Because these nucleoside analogs have the added bonus of allowing sub cellular 
localization imaging for diagnostic applications, exploiting the collective properties of 
these biophores has disclosed the accumulation and metabolism of MCNs within specific 
organelles and provided a means to probe intercellular interactions.  Therefore, metal 
containing nucleosides (MCNs) have the capability to ultimately function as therapeutic 
and diagnostic agents, or “theranostic” agents.   This combined platform can eliminate 
many of the pitfalls associated with the limited therapeutic and diagnostic tools for treating 
orphan diseases such as highly fatal Glioblastoma Multiformae (GBM) brain tumors.  Two 
specific MCNs coined Ir(III)-PPY and Ir(III)-BZQ have been evaluated as a means to 
identify the type of compounds limited by specific nucleoside transporter proteins.  The 
diagnostic capabilities of such compounds have been further exploited to visualize 
intracellular localization and selectivity.  
Initially, I sought to study the pharmacodynamics (what the drug does to the body) 
via in-vivo / ex-vivo analysis with a cell model of the ATCC established brain cancer cell 
line (U-87) for grade 4 glioblastoma brain tumors.  These studies include the mechanisms 
of cytotoxicity and effective concentrations required to be toxic in tumor cells vs. normal 
cells (ATCC fibroblasts).   Quantitative data has been presented examining the ability of 
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metal-containing nucleosides to function as anti-cancer agents against glioblastoma, an 
adherent cancer cell line.  It is also important to state that although Ir(III)-BZQ expresses 
an increased potency over Ir(III)-PPY, a higher potency may not be as efficient in clinical 
applications and may lead to swelling and edema in shorter time frames than a less potent 
therapeutic agent.   
Analysis in a previous project focusing on the MCN Ir(III)-PPY concluded via cell 
cycle analysis that this MCN acts as a kinase inhibitor and produces anti-cancer effects 
against the established ovarian cancer, viral cell model (KB3-1).  Cell-cycle progression is 
also affected in both cervical cancer cells (KB3-1) and brain cancer cells (U87).  Reasons 
why the Ir(III)-PPY nucleoside has a more pronounced effect towards inducing apoptosis 
in U87 cells compared to KB3-1 cells are still unclear and warrant further investigation, as 
the underlying cellular mechanism for this difference is also unknown at this time.    
In reference to the mechanism of cell death associated with MCNs, several 
techniques including flow cytometry analysis and microscopy were conducted to test my 
hypothesis.  Microscopy studies measuring fluorescence associated with these analogs 
demonstrate that both Ir(III)-PPY nucleoside and Ir(III)-BZQ nucleoside are taken up into 
U87 cells in a time- and dose-dependent manner. In this respect, the cellular uptake of 
Ir(III)-BZQ nucleoside is more efficient than that of Ir(III)-PPY nucleoside, and this 
difference correlates with measured differences in their potency.  Dual parameter flow 
cytometry analyses validate that these nucleoside analogues cause apoptosis. Pre-treating 
cells with known nucleoside transport inhibitors reduces the cytotoxicity of Ir(III)-PPY 
nucleoside by blocking its cellular uptake. However, pre-treatment with NMBPR does not 
block the cellular uptake of Ir(III)-BZQ nucleoside.  These results indicate that cellular 
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entry of Ir(III)-PPY nucleoside is mediated by the human equilibrative nucleoside 
transporter one (hENT1) while transport of Ir(III)-BZQ nucleoside occurs via a different 
pathway involving one or more other nucleoside transporters.  
Cell cycle analysis results also provide evidence showing that the Ir(III)-PPY 
nucleoside induces apoptosis, manifested by the increase in sub-G1.  Significant increases 
in the percentages of cell populations at S-phase and G2/M have also been observed.  
Although these results suggest that Ir(III)-PPY nucleoside can affect cell-cycle progression 
in diploid cells, similar results were observed in KB3-1 cells treated with Ir(III)-PPY 
nucleoside.  Collectively, however, conclusions may be drawn indicating that both Ir(III)-
PPY nucleoside and Ir(III)-BZQ nucleoside cause cell death via an apoptotic pathway as 
opposed to necrosis.    
Although structurally similar, the metal-containing nucleosides display unique 
features that highlight how subtle permutations in structure can produce different 
pharmacodynamic effects, This is evident as the potency of Ir(III)-BZQ nucleoside is ~8-
fold lower than Ir(III)-PPY nucleoside.  This difference in potency reflects the ability of 
Ir(III)-BZQ nucleoside to induce apoptosis at lower concentrations. In this case, dual 
parameter FACS analyses measuring propidium iodide (PI) uptake and Alexa Fluor 488 
Annexin V conjugate staining was used to demonstrate that  Ir(III)-PPY nucleoside and 
Ir(III)-BZQ nucleoside induce apoptosis rather than necrosis. These apoptotic effects are 
both dose- and time-dependent, and this result is consistent with previous results measuring 
cellular viability (vide supra).  However, perhaps the most striking difference is the fact 
Ir(III)-PPY nucleoside is transported by hENT1 while Ir(III)-BZQ, the more potent analog, 
does not appear to an effective substrate for hENT1.  The striking difference in the targeted 
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pathways, however, require further studies to first confirm that Ir(III)-PPY nucleoside 
appears to affect cell-cycle progression in U87 whereas Ir(III)-BZQ nucleoside has a 
minimal effect, if any, on cell cycle progression.  
Finally, co-localization studies using high-field microscopy techniques 
demonstrated that Ir(III)-PPY nucleoside accumulates in the nucleus and mitochondria of 
these cancer cells. This last feature indicates that the metal-containing nucleoside is a novel 
chemical probe that can measure nucleoside distribution at the cellular level.   Findings 
within this project also indicate that cellular entry of Ir(III)-PPY nucleoside is mediated via 
an active transport mechanism catalyzed by hENT1 (hENT1) while transport of Ir(III)-
BZQ nucleoside occurs via a different pathway involving one or more other nucleoside 
transporters.  The use of the inhibitor NBMPR in pre-treatment has resulted in a 
chemoprotective effective against Ir(III)-PPY nucleoside in KB3-1 cells. Surprisingly, the 
structurally related analog, Ir(III)-BZQ nucleoside, however, does not appear to be 
transported by hENT1 and therefore undergoes active transport by another nucleoside 
transporter or via passive diffusion.  Indeed, the data provided here indicates that Ir(III)-
PPY nucleoside is transported by hENT1 as pre-treatment with NBMPR blocks its uptake 
in both U87 cells and KB3-1 cells. However, the same cannot be said for the uptake of 
Ir(III)-BZQ nucleoside as pre-treatment with NBMPR does not block its uptake into U87 
cells. Thus, Ir(III)-BZQ nucleoside is most likely a poor substrate for hENT1 and must 
enter the cell via the activity of another nucleoside transporter.   
Collectively, these data provide evidence for the development of a metal-containing 
nucleoside that functions as a therapeutic agent against brain cancer that uses nucleoside 
transporter activity to facilitate cellular entry. Subsequent analyses of the pharmacokinetic 
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effects of MCN biodisposition support the use of MCNs as diagnostic probes via 
fluorescence microscopy analysis of the transport and intracellular localization of these 
luminophores across CNT and ENT nucleoside transporters.   
 
 
 
 
  109 
 
CHAPTER V 
FUTURE DIRECTION 
Although structure-activity relationships (SAR) of MCNs have not been determined, the 
small structural features associated with the various ligands used to synthesize cyclometalated 
iridium nucleoside analogs may be evaluated to alter potency or efficacy amongst this class of 
analogs.  Although many metals are associated with deleterious physiological effects, in specific 
cases this toxicity can be tailored and targeted toward the treatment and diagnosis of cancer cells.  
Combining this cytotoxicity along with properties such as Lewis acidity, redox reactivity, metal 
chelating and coordinating ability and the proclivity to react with biological macromolecules can 
collectively unleash lethal effects tumor cells.(147, 148)      Because of the versatility of metals in 
comparison to carbon and small organic molecules, the formation of highly stable complexes 
synthesized from ruthenium (Ru(II), osmium (Os(II), rhodium (Rh(III) and iridium (Ir(III) have 
emerged as highly selective probes and protein inhibitors.(149)      The geometry of octahedral 
metal coordination complexes, in particular, permit the synthesis of globular, rigid structures with 
shapes similar to the stereochemical complexity of natural products.(150)       
Similar to iridium, cyclometalated ring structures produced by ruthenium octahedral 
coordination complexes have been successfully used to develop repair enzyme inhibitors as 
potential chemotherapeutic agents with exceptional specificity for certain biological moieties.(151)     
  110 
Additional versatility has been observed in platinum cyclometalated octahedral complexes.  Iridium 
metal centers can be easier to synthesize than other metal complexes because they are not as 
unstable or air sensitive.  Recent studies reveal iridium complexes able to serve as asymmetric 
catalysts by directly coordinating with biological substrates and a variety of chemically labile 
ligands that promote configurationally stable metal complexes with increased selectivity.(152)      
The potential of these and other metal complexes to serve as chemotherapeutic agents continues to 
grow with the synthesis and discovery of more versatile metal chemotherapeutics. 
As such, the affinity of CNT and ENT transporters substrates with specific functional 
groups should be considered.  The synthesis of these compounds is accomplished via a “click 
chemistry” mechanism and has resulted in a library of ten metal containing nucleosides 
synthesized to date (Figure 24).  Initial factors such as availability during initial screening tests 
limited the analysis of another MCN, Ir(III)-PBO more thoroughly.   However, preliminary cell 
viability studies with Ir(III)-PBO indicated that it may actually be the most potent of the first three 
compounds studied.  Because the molecular structures of Ir(III)-PPY and Ir(III)-BZQ were also 
similar, in contrast with Ir(III)-PBO, these two MCNs were ultimately selected to facilitate this 
study. Understanding the effects of specific functional groups attached to the cyclometalated 
iridium will also help develop the medicinal chemistry approach to increase potency via specific 
structural augmentations. 
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Figure 24.  A library of ten cyclometalated iridium metal containing nucleosides, 
including Ir(III)-PPY and Ir(III)-BZQ, respectively, in the middle of the top 
row.(132)  
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To further conclude on the pharmacodynamic effects of MCNs on brain cancer cells, a 
comparative analysis of the treatment of U-87 cells (along with additional cell models) treated with 
MCNs and various know cell cycle inhibitors and chemotherapeutic agents should also be 
conducted.  During future experiments, other known chemotherapeutic agents and nucleoside 
analogs such as pentostatin, mimosine, staurosporine cyclosporine and cisplatin may serve as 
possible controls and variables to further indicate the mechanism of cell death via known 
biomarkers associated with apoptotic character. 
When determining the effective concentrations/doses that cause a therapeutic effect in 
future experiments, discrepancies between flow cytometry data and cell viability data must be 
addressed.  For instance, the mitochondria can be used in the pharmacokinetic determination of the 
rate of ATP depletion in the cells.   The interaction of MCNs with mitochondrial pores may also be 
evaluated and potentially visualized via high resolution microscopy to see if the MCN has 
penetrated the mitochondrial matrix or if it is merely trapped between the inner and outer 
membranes.  Based on the conclusion of decreased ATP production after 48 hours, interval analysis 
of ATP levels after 8, 16 and 24 hours will support the concentration and time dependent cytotoxic 
effects of each MCN. This will also lead to the analysis of the use of mitochondrial membrane 
transport proteins in MCN cytotoxicity.   
In addition, specific assays used for measuring the ATP inside the mitochondria will also 
pinpoint cellular mechanisms associated with dysfunctional mitochondria.  When it comes to 
measuring cell viability with greater sensitivity, one specific assay suggested is the ATP assay 
using firefly luciferase; a light assay that is directly proportional to the change in light when 
measuring specific protein levels required to produce light emission generated from the reaction of 
oxygen and ATP.  The measurement of ATP using firefly luciferase is the most commonly applies 
method for estimating the number of viable cells. Contrary to the types of assays previously 
mentioned, the ATP assay is the fastest cell viability assay to use, although generally much more 
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expensive.  With the elimination of incubation time required before analysis, the resulting 
luminescent signal typically glows for approximately five hours.(153)       
The overexpression of key nucleoside transporters is a potential biomarker for the 
treatment of many types of cancer with nucleoside analogs.  Western Blot analysis can be used to 
determine protein levels of CNT and ENT proteins in various cell types.  Another method to 
evaluate the activity of transporter proteins is the use of siRNA to knock down the specific protein 
of interest.  The interaction of substrates and inhibitors specific to individual transporters, such as 
NMBPR, also generate similar results.  Using the ubiquitously transported nucleoside adenosine, 
for instance, was found to be a key way to prove the uptake of MCNs via nucleoside transporters, 
opposed to the siRNA analysis of each of the seven (7) individual isoforms of CNT and ENT 
proteins independently. 
Theranostics have the potential to revolutionize medicine and healthcare.   The reasons for 
the especially high cost of healthcare in the US can be attributed to a number of factors ranging 
from inappropriate healthcare and the rising cost of medical technology and prescription drugs.  As 
the landscape of molecular diagnostics continues to change, a new focus on personalized medicine 
has emerged and continues to be driven by numerous factors.(154)       The current lack of effective 
diagnostics tools, consumers demanding more affordable medicines and less side effects and the 
aging baby boomer population are all contributing factors.  Clinicians and Pharmaceutical 
companies alike can benefit from using the unique theranostics platform to improve the outcome 
of patients.(155)    Ultimately, however, in order for the future of theranostics to flourish, there 
must be a bridge in the gap between the overlapping disciplines of organic and inorganic synthesis 
with medicinal and clinical chemists, radiologist and oncologist to optimize the capabilities of 
improved molecular, therapeutic and diagnostic tools.   
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